<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006941.pub2" GROUP_ID="MOVEMENT" ID="208705021509505286" MERGED_FROM="" MODIFIED="2016-08-19 11:46:53 +0100" MODIFIED_BY="Ema Roque" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;/p&gt;" NOTES_MODIFIED="2016-08-17 14:33:15 +0100" NOTES_MODIFIED_BY="Ema Roque" REVIEW_NO="003" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2016-08-17 11:36:05 +0100" MODIFIED_BY="Ema Roque">
<TITLE>Opioids for restless legs syndrome</TITLE>
<CONTACT>
<PERSON ID="38D0FA0C82E26AA201BA4B547DC85853" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Gilmar</FIRST_NAME>
<MIDDLE_INITIALS>F</MIDDLE_INITIALS>
<LAST_NAME>Prado</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>gilmarunifesp@yahoo.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP/>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 5081 6629</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-08-17 11:36:05 +0100" MODIFIED_BY="Ema Roque">
<PERSON ID="z1310211150566051509557010637683" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>César</FIRST_NAME>
<MIDDLE_INITIALS>Osório</MIDDLE_INITIALS>
<LAST_NAME>de Oliveira</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>cesarbete@uol.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="71568C7F82E26AA200CE0284C573E0D4" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Luciane</FIRST_NAME>
<MIDDLE_INITIALS>BC</MIDDLE_INITIALS>
<LAST_NAME>Carvalho</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<POSITION/>
<EMAIL_1>lucianebizari@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Claudio Rossi, 394</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>CEP 01547-000</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 50816629</PHONE_1>
<PHONE_2>+55 11 50816629</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1310211137131893921692831170592" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Karla</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Carlos</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Ka.carlos1@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="73EBB10682E26AA201E0E19D9634A52F" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Cristiane</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Conti</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Neurologist, PhD</POSITION>
<EMAIL_1>contic@terra.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Morphology</DEPARTMENT>
<ORGANISATION>Universidade Federal do Maranhão</ORGANISATION>
<ADDRESS_1>Av. dos Portugueses, 1966</ADDRESS_1>
<ADDRESS_2>Bacanga</ADDRESS_2>
<CITY>São Luis</CITY>
<ZIP>65080-805</ZIP>
<REGION>Maranhão</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 98 32728521</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="AFBB514F82E26AA20100271A20CF4B41" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Marcio</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>de Oliveira</LAST_NAME>
<SUFFIX/>
<POSITION>Physician</POSITION>
<EMAIL_1>docmmo@uol.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Morphology</DEPARTMENT>
<ORGANISATION>Universidade Federal do Maranhão</ORGANISATION>
<ADDRESS_1>Av dos Portugueses 1966</ADDRESS_1>
<ADDRESS_2>Bacanga</ADDRESS_2>
<CITY>São Luis</CITY>
<ZIP>65080-805</ZIP>
<REGION>Maranhão</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7B97BA2482E26AA2014A55948F8A57B9" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Lucila</FIRST_NAME>
<MIDDLE_INITIALS>BF</MIDDLE_INITIALS>
<LAST_NAME>Prado</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Coordinator of Neuro-Sono Sleep Medicine</POSITION>
<EMAIL_1>lucilaunifesp@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Claudio Rossi,394</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>01547-000</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 5081 6629</PHONE_1>
<PHONE_2>+55 11 55728205</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="38D0FA0C82E26AA201BA4B547DC85853" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Gilmar</FIRST_NAME>
<MIDDLE_INITIALS>F</MIDDLE_INITIALS>
<LAST_NAME>Prado</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>gilmarunifesp@yahoo.com.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Neurology</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP/>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 5081 6629</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-05-26 18:30:01 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="11" MONTH="4" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="11" MONTH="4" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="11" MONTH="5" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="6" YEAR="2016"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2016"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="6" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2016-06-08 03:00:43 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2016-06-08 03:00:16 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-06-08 03:00:16 +0100" MODIFIED_BY="[Empty name]">
<NAME>Escola Paulista de Medicina, Universidade Federal de São Paulo</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION>
<P>Salary</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2016-06-08 03:00:43 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-06-08 03:00:43 +0100" MODIFIED_BY="[Empty name]">
<NAME>CAPES and CNPq</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION>
<P>Government Agencies for research support</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-07-06 22:01:12 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-07-06 22:01:12 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2016-05-25 17:18:25 +0100" MODIFIED_BY="[Empty name]">Opiods for restless legs syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2016-07-06 22:01:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>Background</I>
</P>
<P>Restless legs syndrome (RLS) is a very common neurological disorder in which patients complain of an intense need to move their legs, and unpleasant sensations felt deep in their legs, all occurring while at rest, mostly at bedtime. The number of patients complaining of RLS varies according to race, gender, age, country, and health status. About 5% to 10% of people are affected; , and, among these, 2% to 5% need continual pharmacological treatment (medication). When RLS does not respond to medications generally used for Parkinsons Disease and epilepsy, their doctors often prescribe opioids.</P>
<P>
<I>Question</I>
</P>
<P>Are opioids effective and safe for people with RLS?</P>
<P>
<I>Methods</I>
</P>
<P>We searched the literature for studies in any language, published or not, that considered opioids for the treatment of RLS</P>
<P>
<I>Results</I>
</P>
<P>We included one randomised controlled clinical trial with moderate risk of bias that tested a combination of oxycodone and naloxone against placebo capsules, taken twice daily in participants whodid not respond to more usual medications. Researchers used the International RLS severity scale to find out if patients were improved after 12 weeks of treatment. Particpants receiving the combined oxycodone and naloxone reported improvement in RLS symptoms, Quality of life, and sleep quality; 42% of the drug group were symptom-free.</P>
<P>
<I>Discussion</I>
</P>
<P>The study was well designed overall, but was at a high risk of bias due to the high percentage of participants who withdrew from treatment (attrition bias). Eighty-four percent of the drug group developed adverse events, which were mostly related to the gastrointestinal system, headache, fatigue, and sleepiness (somnolence); 9.8% left the study because of the adverse events.</P>
<P>
<I>Conclusion</I>
</P>
<P>The use of opioids for the treatment of RLS in patients resistant to conventional treatment is supported by low-quality evidence. Prescription of these medications should be based on clinical experience, and caution used due to the potential for abuse, dependency, and adverse events. No patient on opioids complained that their symptoms worsened.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-07-06 00:02:21 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>Restless legs syndrome (RLS) is a distressing and common neurological disorder that may have a huge impact in the quality of life of those with frequent and intense symptoms. Patients complain of unpleasant sensations in the legs, at or before bedtime, and feel an urge to move the legs, which improves with movement, such as walking. Symptoms start with the patient at rest (e.g. sitting or lying down), and follow a circadian pattern, increasing during the evening or at night. Many pharmacological intervention are available for RLS, including drugs used to treat Parkinson's disease (L-Dopa and dopaminergic agonists), epilepsy (anticonvulsants), anxiety (benzodiazepines), and pain (opioids). Dopaminergic drugs are those most frequently used for treatment of RLS, but some patients do not respond effectively and require other medication. Opioids, a class of medications used to treat severe pain, seem to be effective in treating RLS symptoms, and are recommended for patients with severe symptoms, because RLS and pain appear to share the same mechanism in the central nervous system. All available drugs are associated to some degree with side effects, which can impede treatment. Opioids are associated with adverse events such as constipation, tolerance, and dependence. This justifies the conduct of a systematic review to ascertain whether opioids are safe and effective for treatment of RLS.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-07-30 11:57:46 +0100" MODIFIED_BY="[Empty name]">
<P>To asses the effects of opioids compared to placebo treatment for restless legs syndrome in adults.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled trials, CENTRAL 2016, issue 4 and MEDLINE, EMBASE, and LILACS up to April 2016, using a search strategy adapted by Cochraneto identify randomised clinical trials. We checked the references of each study and established personal communication with other authors to identify any additional studies. We considered publications in all languages.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled clinical trials of opioid treatment in adults with idiopathic RLS.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently screened articles, independently extracted data into a standard form, and assessed for risk of bias. If necessary, they discussed discrepancies with a third researcher to resolve any doubts.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>We included one randomised clinical trial (N = 304 randomised; 204 completed; 276 analysed) that evaluated opioids (prolonged release oxycodone/naloxone) versus placebo. After 12 weeks, RSL symptoms had improved more in the drug group than in the placebo group (using the IRLSSS: MD -7.0; 95% CI -9.69 to -4.31 and the CGI: MD -1.11; 95% CI -1.49 to -0.73). More patients in the drug group than in the placebo group were drug responders (using the IRLSSS: RR 1.82; 95% CI 1.37 to 2.42 and the CGI: RR1.92; 95% ICI 1.49 to 2.48). The proportion of remitters was greater in the drug group than in the placebo group (using the IRLSSS: RR 2.14; 95% CI 1.45 to 3.16). Quality of life scores also improved more in the drug group than in the placebo group (MD -0.73; 95% CI -1.1 to -0.36). Quality of sleep was improved more in the drug group measured by sleep adequacy (MD -0.74; 95% CI -1.15 to -0.33), and sleep quantity (MD 0.89; 95% CI 0.52 to 1.26). </P>
<P>There was no difference between groups for daytime somnolence, trouble staying awake during the day, or naps during the day. More adverse events were reported in the drug group (RR 1.22; 95% CI 1.07 to 1.39). The major adverse events were gastrointestinal problems, fatigue, and headache. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-07-06 00:02:21 +0100" MODIFIED_BY="[Empty name]">
<P>Opioids seem to be effective for treating RLS symptoms, but there are no definitive data regarding the important problem of safety. This conclusion is based on only one study with a high dropout rate (low quality evidence).</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-07-06 00:12:09 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-06-08 03:03:34 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-06-08 03:03:34 +0100" MODIFIED_BY="[Empty name]">
<P>Restless legs syndrome (RLS) is a sensorimotor disorder characterised by a distressing urge to move the legs, and sometimes, other parts of the body as well, usually accompanied by a marked sense of discomfort or pain in the leg or other affected body parts (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>).</P>
<P>The prevalence of RLS is estimated at 5% to 15% in adults. It is more common in women, and can affect children as well (<LINK REF="REF-Picchietti-2005" TYPE="REFERENCE">Picchietti 2005</LINK>; <LINK REF="REF-Picchietti-2007" TYPE="REFERENCE">Picchietti 2007</LINK>[ <LINK REF="REF-Yeh-2012" TYPE="REFERENCE">Yeh 2012</LINK>). When frequency, severity, or a combination of symptoms is added to the diagnostic criteria, the prevalence of RLS ranges from 2.2% to 7.9%. If the diagnosis is based on a clinical interview, taking into account all possible differential diagnoses, the prevalence declines to between 1.9% and 4.6% (<LINK REF="REF-Ohayon-2012" TYPE="REFERENCE">Ohayon 2012</LINK>).<BR/>
</P>
<P>Other features commonly found in adults with RLS include sleep disturbance, daytime fatigue, and decreased quality of life ratings, mostly in patients who also have iron deficiency anaemia (<LINK REF="REF-Allen-2013" TYPE="REFERENCE">Allen 2013</LINK>; <LINK REF="REF-Picchietti-2005" TYPE="REFERENCE">Picchietti 2005</LINK>).</P>
<P>The physical examination is typically normal. restless leg syndrome may be either idiopathic (primary RLS, which often has a familial component) or secondary, occurring in conjunction with other medical conditions, particularly iron deficiency anaemia, pregnancy, or end-stage renal disease. Secondary RLS tends to remit without evidence of reoccurrence when the secondary condition is resolved, for example, after renal transplantation in patients with end-stage renal disease, and postpartum in women with RLS during pregnancy (<LINK REF="REF-Lee-2001" TYPE="REFERENCE">Lee 2001</LINK>; <LINK REF="REF-Winkelmann-2002" TYPE="REFERENCE">Winkelmann 2002</LINK>).</P>
<P>Periodic leg movements in sleep (PLMS) are characterized by brief (0.5- to 5.0-second) lower-extremity movements during sleep, which typically occur at 20- to 90-second intervals, most commonly during the first three hours of sleep. The affected individual is usually not aware of the movements or of the associated transient partial arousals (<LINK REF="REF-Picchietti-2005" TYPE="REFERENCE">Picchietti 2005</LINK>; <LINK REF="REF-Trenkwalder-2005" TYPE="REFERENCE">Trenkwalder 2005</LINK>). Overall, 80% to 90% of individuals with RLS have PLMS, but PLMS are not necessarily associated with RLS (<LINK REF="REF-Hornyak-2006" TYPE="REFERENCE">Hornyak 2006</LINK>; <LINK REF="REF-Rye-2012" TYPE="REFERENCE">Rye 2012</LINK>). The prevalence of PLMS in the general population is 3.9% (<LINK REF="REF-Ohayon-2002" TYPE="REFERENCE">Ohayon 2002</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>The treatment of RLS includes pharmacological and non-pharmacological therapies. The most common pharmacological agents used in clinical practice are levodopa, dopamine agonists, opioids, benzodiazepines, and anticonvulsants (<LINK REF="REF-Garcia_x002d_Borreguero-2013" TYPE="REFERENCE">Garcia-Borreguero 2013</LINK>; <LINK REF="REF-Trenkwalder-2005" TYPE="REFERENCE">Trenkwalder 2005</LINK> ).</P>
<P>The precise mechanisms by which opiates ameliorate RLS are not well understood. Opiate receptors have been identified in the dorsal horn, where they are believed to participate in the regulation of incoming nociceptive sensory information. Opiates are also highly concentrated in brainstem areas, around the periaqueductal grey and in the basal ganglia (striatum, substantia nigra); each of these areas could be sites in which the opioids act to improve symptoms of RLS (<LINK REF="REF-Sandyk-1987" TYPE="REFERENCE">Sandyk 1987</LINK>). Involvement of the dopamine system in RLS pathophysiology seems probable, but involvement of the opiate system is less clear.</P>
<P>Narcotic medications generally have a relatively low potential for addiction, and cause little tolerance in the RLS population (<LINK REF="REF-Winkelmann-2002" TYPE="REFERENCE">Winkelmann 2002</LINK>). Side effects include nausea, sedation, dizziness, and constipation. There are still concerns about the potential for abuse, addiction, and practical problems, so the treatment of RLS with opioids remains controversial.</P>
<P>The essentially normal presynaptic dopaminergic binding studies using F-dopa PET or B-CIT-SPECT (diagnostic imaging tools) in patients with RLS lend support to the hypothesis that dopaminergic neurons and spinal pathways could be involved more in the pathophysiological mechanisms of the syndrome than the nigrostriatal system (<LINK REF="REF-Wetter-2004" TYPE="REFERENCE">Wetter 2004</LINK>).</P>
<P>Althoug dopamine can be increased in the synaptic cleft of patients with RLS, the strongest evidence for a dopaminergic role in the pathophysiology of RLS comes from the pharmacological response to medications that increases dopamine function (<LINK REF="REF-Allen-2004" TYPE="REFERENCE">Allen 2004</LINK>; <LINK REF="REF-Earley-2013" TYPE="REFERENCE">Earley 2013</LINK>). Functional imaging studies have shown reduced fluoro dopa uptake or reduced D2 receptor binding in the corpus striatum (<LINK REF="REF-Wetter-2004" TYPE="REFERENCE">Wetter 2004</LINK>).</P>
<P>Iron is a cofactor in dopamine production, and RLS patients exhibit a deficiency of iron in the brain. Studies with iron-deprived rats indicate that low CSF ferritin and high transferrin can be expected to occur with reduced brain iron (<LINK REF="REF-Allen-2004" TYPE="REFERENCE">Allen 2004</LINK>; <LINK REF="REF-Rizzo-2013" TYPE="REFERENCE">Rizzo 2013</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>The endogenous opioid system plays a role in pain transmission , and there is evidence of opioid receptors involvement in the pathogenesis of RLS (<LINK REF="REF-Hening-1986" TYPE="REFERENCE">Hening 1986</LINK>; <LINK REF="REF-Mizoguchi-2014" TYPE="REFERENCE">Mizoguchi 2014</LINK>). A post-mortem study of the brains of patients with RLS showed deficiencies of beta-enkephalin and met-endorphin in the thalamus (<LINK REF="REF-Walters-2009" TYPE="REFERENCE">Walters 2009</LINK>), which also suggests a direct implication of this system in the pathogenesis of RLS symptoms. Furthermore, mu-receptors in rats presented signs suggestive of RLS, and interestingly, iron deficiency, which is somehow related to the clinical picture of RLS (<LINK REF="REF-DeAndrade-2013" TYPE="REFERENCE">DeAndrade 2013</LINK>; <LINK REF="REF-Earley-2014" TYPE="REFERENCE">Earley 2014</LINK>). Hence, there is a body of data supporting the hypothesis that opioid drugs can improve endogenous opioid system function, thus providing improvement or even complete relief of RLS symptoms.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>Many pharmacological intervention are available for RLS, including drugs used to treat Parkinson's disease (L-Dopa, dopaminergic agonists), epilepsy (anticonvulsants), anxiety (benzodiazepines), and pain (opioids). Dopaminergic drugs are the most frequent treatment used for RLS, but some patients do not respond effectively and require other medication. Opioids, a class of medications used to treat severe pain, seem to be effective in treating RLS symptoms and are recommended for patients with severe symptoms, because RLS and pain appear to share the same mechanism in the central nervous system. All available drugs are associated to some degree with side effects, which can impede treatment. Dopaminergic drugs can cause worsening of symptoms, which is known as augmentation, anticonvulsant drugs are associated with somnolence, and benzodiazepines are beneficial only for minor symptoms of RLS. Opioids are associated with adverse events such as constipation, tolerance, and dependence. This justifies the conduct of a systematic review to ascertain whether opioids are safe and effective for the treatment of RLS.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the efficacy and safety of opioid treatment for idiopathic RLS.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-07-05 23:48:39 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-06-08 03:03:13 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) and quasi-RCTs (defined as trials using inadequate allocation assignment such as date of birth, day of the week or month of the year, person's medical record number, or simply allocating every alternate person). We considered studies with a parallel or a cross-over design.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-06-08 03:03:13 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>We considered children and adults who met any clinical criteria for idiopathic RLS (<LINK REF="REF-ICSD-2014" TYPE="REFERENCE">ICSD 2014</LINK>; <LINK REF="REF-Walters-1995" TYPE="REFERENCE">Walters 1995</LINK>). A recent version of the criteria for clinical diagnostic lists four essential features (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>):</P>
<OL>
<LI>An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs (sometimes the urge to move is present without the uncomfortable sensations, and sometimes the arms or other body parts are involved in addition to the legs);</LI>
<LI>The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity, such as lying or sitting;</LI>
<LI>The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues;</LI>
<LI>The urge to move or unpleasant sensations are worse in the evening or night than during the day, or only occur in the evening or night (when symptoms are very severe, the worsening at night may not be noticeable but must have been previously present).</LI>
</OL>
<P>Some of the trials identified included patients with Periodic Limb Movement Disorder (PLMD), which is commonly associated with RLS. Studies exclusively examining patients with PLMD (without symptoms of restless legs) were excluded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>We excluded studies that included patients with secondary forms of RLS, such as metabolic, neuropathic, or renal disease.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>We included trials that compared opioid drugs to placebo, to no treatment, or to other drug treatments.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-08-07 22:50:31 +0100" MODIFIED_BY="[Empty name]">
<P>Improvement of restless legs symptoms, as assessed by a validated scale (<LINK REF="REF-Allen-2001" TYPE="REFERENCE">Allen 2001</LINK>; <LINK REF="REF-IRLSSG-2003" TYPE="REFERENCE">IRLSSG 2003</LINK>).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Subjective sleep quality (any description about sleep quality, i.e., well-being, improvement of fatigue);</LI>
<LI>Sleep quality, as measured by overnight polysomnography (sleep efficiency, total sleep time, arousal index, PLMS index);</LI>
<LI>Quality of life, as measured by a validated scale, such as the SF-36;</LI>
<LI>Adverse events, described in terms of:</LI>
<OL>
<LI>Number of withdrawals due to adverse events;</LI>
<LI>Number of patients with any adverse events associated with interventions.</LI>
</OL>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Cochrane Central Register of Controlled Trials, (CENTRAL) 2016, Issue 4, in <I>The Cochrane Library</I> (accessed April 2016; <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</LI>
<LI>MEDLINE (1966 to April 2016), using the optimally sensitive strategy developed for the Cochrane Collaboration for the identification of randomised controlled trials ;(<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</LI>
<LI>EMBASE (1980 to April 2016), using a search strategy adapted from one developed for the Cochrane Collaboration for the identification of randomised controlled clinical trials (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</LI>
<LI>LILACS (1982 to April 2016), using a search strategy adapted from one developed for the Cochrane Collaboration for the identification of randomised controlled clinical trials (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI>
</OL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed references from original papers and abstracts, reviews, systematic reviews, and meta-analysis to identify any additional studies.<BR/>We contacted authors of the included studies to ask if they knew of any relevant unpublished material.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-07-05 23:48:39 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>The search strategies described above were used to obtain titles and abstracts of relevant studies, which were independently screened by LC and KC. They initially retained review articles that might include relevant data or information on trials. The review authors independently assessed the retrieved abstracts, and if necessary, the full text of these studies to determine which studies met the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-06-08 02:47:22 +0100" MODIFIED_BY="[Empty name]">
<P>The same review authors independently extracted data, using standard data extraction forms. The two review authors entered the data into Review Manager software once all disagreements had been addressed. They had studies reported in non-English language journals translated before being assessed. Where more than one publication of a trial existed, the papers were grouped, and for each available outcome, results were extracted from the publication with the most complete data. We requested further information from the original author by written correspondence as required, and any relevant information obtained in this manner was included in the review. We resolved all disagreements by consensus, with a third review author if needed.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-07-05 23:48:39 +0100" MODIFIED_BY="[Empty name]">
<P>The same two review authors independently assessed the risk of bias of the included studies, without blinding to authorship or journal. They resolved any disagreement by discussion.</P>
<P>We incorporated the 'risk of bias' assessments into the 'risk of bias' tables, as described in the Cochrane Hankbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We considered these criteria: adequate sequence generation, allocation concealment, blinding of participants, personnel, and outcome assessment, incomplete outcome data, selective outcome reporting, and other biases. We assigned 'low risk', 'high risk', or 'unclear risk' judgements to each criterion. 'Unclear risk' indicated there was insufficient information to permit a clear judgement.</P>
<P>We used the GRADE approach to assess quality of the evidence for each outcome across trials, and presented the results in a 'Summary of findings' table. We categorised the primary outcomes at the highest level, and downgraded them due to the following study limitations (risk of bias): limitations in design, inconsistency of results, indirectness of evidence, imprecision of results, and publication bias. We decreased the quality of the evidence by one point if there were serious problems with the risk of bias criteria, or two points if there were very serious problems.</P>
<P>For the 'Summary of findings' table, we analysed the primary outcome: RLS Symptoms, using the International RLS Severity Scale (IRLSSS) and the Clinical Global Impression severity</P>
<P>scale (CGI); drug responders, using the IRLSSS and CGI, and Remitters (decreased symptoms), using the IRLSSS; and the secondary outcomes: adverse events and quality of life (Summary of findings table 1).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-06-08 02:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>We entered and analysed data in Review Manager 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) software. We constructed the 'Summary of findings' tables using the GRADE profiler 3.2.2 software (<LINK REF="REF-GRADEpro-2014" TYPE="REFERENCE">GRADEpro 2014</LINK>). For dichotomous variables, risk ratios (RR) with 95% confidence intervals (95% CI) were calculated using the fixed-effects model. Mean differences (MD) with 95% confidence intervals were calculated for continuous outcome variables, using the fixed-effects model.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-06-08 02:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>Only one trial was included, in a simple parallel group design. In future updates, we may include cross-over trials, only if they allow pooling of data and analysis according to the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We will evaluate the two cross-over periods with a paired analysis, and the carry-over effect</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-06-08 02:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>In suspected cases of missing data, we contacted the primary investigator of the study.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-06-08 02:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>As only one study was included, we did not assess heterogeneity. In future updates, we will assess heterogeneity (with the Chi² test), which we will assume to be present when the significance level is lower than 0.10 (P &lt; 0.10). When significant heterogeneity is present, we will attempt to explain the differences based on clinical characteristics of the included studies.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-06-08 02:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>To reduce reporting bias, we contacted as many authors who are involved in RLS research as possible, and asked about any unpublished trials of which they might be aware. We also search the International Committee of Medical Journal Editors for trials that were registered and not published. We had planned to use a funnel plot (trial effect versus trial size) to explore the possibility of publication bias, but did not found sufficient studies (10 or more) for any of the primary analyses.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-06-08 02:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>As there was only one trial, we did not pool the data with a meta-analysis. In futures updates, for clinically homogeneous studies, we will pool outcomes in meta-analyses, using the fixed-effect model as a default, and the inverse variance method.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-06-08 02:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>We did not performed subgroup analysis in this review. In future updates, if a sufficient number of studies (more than 10) are eligible, we will perform subgroup analyses according to age, gender, and duration of treatment. We will categorize periods of treatment as short-term (up to four weeks), or long-term (more than four weeks).<BR/>
</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-06-08 02:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>We did not perform sensitivity analyses, as only one trial was included. Assuming we have sufficient trials in future updates, we will perform sensitivity analyses by omitting trials that include participants with different clinical characteristics, or trials with higher risk of bias.The following strategies will be used for the sensitivity analyses:</P>
<OL>
<LI>Separating RCTs published as abstracts.</LI>
<LI>Separating RCTs of lower risk of bias as assessed by allocation concealment.</LI>
<LI>Separating RCTs without an intention-to-treat analysis.</LI>
<LI>Separating cross-over studies from the analysis.</LI>
</OL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-07-06 00:09:25 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-06-08 03:02:57 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2016-06-08 02:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>Our search of electronics databases yielded a total of 2935 publications with 45 duplicate records: 246 records from CENTRAL, 2204 from MEDLINE, 483 from EMBASE, none from LILACS, and two from manual sources (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).. After analysing the title and abstracts, four of these publications were selected for full-text analysis; their eligibility was subsequently confirmed. One study was published first as an abstract in 1991, but we retained only the complete publication for analysis (<LINK REF="STD-Kaplan-1993" TYPE="STUDY">Kaplan 1993</LINK>). <LINK REF="STD-Allen-1992" TYPE="STUDY">Allen 1992</LINK>, <LINK REF="STD-Kaplan-1993" TYPE="STUDY">Kaplan 1993</LINK> and <LINK REF="STD-Walters-1993" TYPE="STUDY">Walters 1993</LINK> were excluded because there were insufficient individual cross-over data available to analyse the variance of the two periods, the wash-out period, or the first period. We ultimately included one study(<LINK REF="STD-Trenkwalder-2013" TYPE="STUDY">Trenkwalder 2013</LINK>). </P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-06-08 03:02:57 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Trenkwalder-2013" TYPE="STUDY">Trenkwalder 2013</LINK> was a randomised, double-blind, parallel, multicentre trial that enrolled 304 adults with RLS. The patients were recruited from 55 sites in Austria, Germany, Spain, and Sweden. They received progressive doses of prolonged-release oxycodone (maximum 40 mg taken twice daily) and naloxone (maximum 20 mg taken twice daily), or placebo. The investigators used the IRLSSS to assess RLS symptoms, responders and remitters, and the Clinical Global Impression (CGI) scales to assess RLS symptoms, adverse events, and proportion of responders. Subjective sleep change was measured with the Medical Outcome Study (MOS). Change in disease-specific quality of life was assessed with the RLS-QoL questionnaire. Authors considered responders those patients that scored 50% less in the IRLSSS and those who declared themselves "much improved" or "very much improved" in the CGI scale; remitters those patients that scored 10 or less in the IRLSSS at the end of treatment; reduced symptoms those patients that scored any value less compared to the baseline score. </P>
<P>One hundred patients dropped out of the study due to adverse events, lack of therapeutic effect, patient choice, or administrative reasons. Analysis was completed on a sample of 276 participants according to the intention-to-treat principle, which included all participants who had received at least one dose of the medication or placebo, and for whom follow-up data were available. The included patients had a high mean IRLSSS at baseline (31.6 ± 4.7). We contacted the first author (Dr Claudia Trenkwalder) on 8 November 2013 to ask her how she dealt with the missing data.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-06-08 02:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Allen-1992" TYPE="STUDY">Allen 1992</LINK>: a randomised, double-blind, cross-over trial of six adult patients. The patients had PLMS and were all diagnosed with RLS on retrospective review. The patients were recruited from The Johns Hopkins Sleep Center, Baltimore, MD, USA. They received progressive doses of propoxyphene (maximum 300 mg), carbidopa/levodopa (maximum 100mg/200mg), or placebo for two weeks prior to polysomnographic studies. We contacted the first author (Dr. Richard Allen) on 20 October 2013, who provided some important information, but the available data were not sufficient or sufficiently detailed to enable inclusion of the study in this review.</P>
<P>
<LINK REF="STD-Kaplan-1993" TYPE="STUDY">Kaplan 1993</LINK>: a randomised, double-blind, cross-over trial of six adult patients with PLMS who were all diagnosed with RLS on retrospective review. This new sample of patients was recruited from The Johns Hopkins Sleep Center, Baltimore, MD, USA. They received progressive doses of propoxyphene (maximum 200 mg), carbidopa/levodopa (maximum 100 mg/200 mg), or placebo for two weeks prior to polysomnographic studies. We contacted one of the authors (Dr. Richard Allen) on 20 October 2013, who provided some important information, but the available data were not sufficient or sufficiently detailed to enable inclusion of the study in this review.</P>
<P>
<LINK REF="STD-Walters-1993" TYPE="STUDY">Walters 1993</LINK>: a randomised, double-blind, cross-over trial of 11 adult patients with RLS and PLMS. The diagnosis of RLS was established clinically by the presence of: abnormal sensations, primarily in the legs, motor restlessness, and worsening of paraesthesias and motor restlessness at night and at rest. The patients were recruited from the Lyons VA Medical Center, UMDNJ-Robert Wood Johnson University Hospital, and the Sleep Disorders Center of Columbia Presbyterian Medical Center. They received progressive doses of oxycodone or placebo under guidance of a member of the research group, to relieve symptoms. Oxycodone or placebo capsules were tapered off in three days, and the second-phase dose titration started immediately. Paresthesias, motor restlessness, and daytime alertness were rated on a symptom severity scale of zero to four, for two weeks prior to polysomnographic studies, and on the night of polysomnography. We contacted the first author (Dr Arthur Walters) on 16 October 2013, who provided some important information, but again, the available data were not sufficient or sufficiently detailed to enable inclusion of the study in this review.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-07-06 00:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>The 'Risk of bias' assessments for the included study can be found in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2016-06-08 02:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>Low risk: the randomisation was conducted with a validated interactive response technology system that automated the random assignment of treatment groups to randomisation numbers by site, in blocks of four.<BR/>
</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-04-20 00:23:13 +0100" MODIFIED_BY="[Empty name]">
<P> Low risk for performance bias: matching placebo tablets (identical in appearance, colour, and taste).</P>
<P>Low risk for detection bias: during the double-blind phase, patients and all personnel involved in the conduct and interpretation of the study (including investigators, site personnel, and sponsor staff) were masked to treatment assignment.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-06-08 02:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>High risk: a total of 306 patients was randomised, but only 174 completed the 12 week study; intention-to-treat analysis was provided.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-07-06 00:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>Low risk: all relevant clinical outcomes were analysed; no subgroup analysis was performed; supplementary data was also available.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-06-08 02:47:23 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear risk: study was proposed by Mundipharma; the principle investigator and three investigators declared conflict of interest with this pharmaceutical company.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-07-06 00:09:25 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome measure</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">RLS Symptoms</HEADING>
<P>In the <LINK REF="STD-Trenkwalder-2013" TYPE="STUDY">Trenkwalder 2013</LINK> study (N = 276), RLS symptoms, measured on the IRLSSS were reduced more in the opioids group than in the placebo group (MD -7.0; 95% CI -9.69 to -4.31; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Symtoms measured on the scale also improved more in the opioid group than in the placebo group (MD -1.11; 95% CI -1.49 to -0.73; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; ).The proportion of drug responders measured on the IRLSSS was greater in the opioid group than in the placebo group (RR 1.82; 95% CI 1.37 to 2.42; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). Measured on the CGI scale, the proportion of participants who responded in the opioid group was higher than in the placebo group (RR 1.92; 95% CI 1.49 to 2.48; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; <U>)</U>.The proportion of remitters, measured by the IRLSSS was greater in the opioid group than in the placebo group (RR 2.14; 95% CI 1.45 to 3.16; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). The quality for these three outcomes was downgraded to low because of attrition bias (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Quality of Sleep</HEADING>
<P>Quality of sleep was improved in the drug group more than in the placebo group, measured by sleep adequacy (MD -0.74; 95% CI -1.15 to -0.33; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>); and sleep quantity (MD 0.89; 95% CI 0.52 to 1.26; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). There was no significant difference between groups for daytime somnolence (MD 0,21; 95% CI -0.13 to 0.55; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), trouble staying awake during the day (MD 0,13; 95% CI -0.19 to 0.45; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>), or naps during the day (MD 0,01; 95% CI -0.32 to 0.34; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of LIfe</HEADING>
<P>Quality of life improved more in the opioid group than in the placebo group (MD -0.73; 95% CI -1.10 to -0.36; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>;). The quality of evidence for this outcome was downgraded from to low because of attrition bias (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse Events</HEADING>
<P>
<LINK REF="STD-Trenkwalder-2013" TYPE="STUDY">Trenkwalder 2013</LINK> (N = 304) reported more adverse events (gastrointestinal problems, fatigue, and headache) in the opioid group than in the placebo group (RR 1.22; 95% CI 1.07 to 1.39; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>). Thirty patients (9.8%) left the study for drug-related adverse events. The quality of the evidence for this outcome was downgraded to low because of attrition bias (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-07-06 00:12:09 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2016-07-06 00:10:01 +0100" MODIFIED_BY="[Empty name]">
<P>In the <LINK REF="STD-Trenkwalder-2013" TYPE="STUDY">Trenkwalder 2013</LINK> study, patients in the oxycodone group showed improvements in RLS symptom and quality of life at week 12. Adverse events were significantly more common in the oxycodone group. The symptoms score mean difference was seven points less (CI: -9.69 to -4.31) in the IRLSSS, and one point less (CI: -1.49 to -0.73) in the CGI in the opioid group after 12 weeks of treatment. Although the quality of life improved only marginally, this finding could be related to the observational period, which may have been too short to provide an accurate perception of that impact. All patients in the opioid group reduced symptoms and improved quality of life and quality of sleep.</P>
<P>Despite the large number of participants who did not complete the planned 12 weeks of treatment, this study provided essential information about the use of opioids to relieve RLS symptoms. Although only 174 patients completed the planned 12 weeks of treatment (100 patients, or 33%, discontinued), analysis was done according to the intention-to-treat principle, and all participants who took at least one dose of medication (or placebo) and provide data during the first week of follow-up were analysed. It is important to state that the reduction of RLS symptoms was significant as early as the first week of treatment, suggesting that this intervention could relieve patients' symptoms quickly. The number of drug responders in the oxycodone/naloxone group was greater than in the placebo group, and there were twice as many drug remitters (patients who became symptoms-free) in the oxycodone/naloxone group than in the placebo group, resulting in a low effect of the intervention. The adverse events reported by <LINK REF="STD-Trenkwalder-2013" TYPE="STUDY">Trenkwalder 2013</LINK> low the effect of the intervention, which is an important contribution to our understanding of the impact of opioid treatment on patients. Opioids are classically used to treat pain, and the most important concern about their use is the potential for abuse and dependency, although it might not be an issue for RLS patients (<LINK REF="REF-Aurora-2012" TYPE="REFERENCE">Aurora 2012</LINK>; <LINK REF="REF-Silver-2011" TYPE="REFERENCE">Silver 2011</LINK>; <LINK REF="REF-Walters-2001" TYPE="REFERENCE">Walters 2001</LINK>). Opioids are associated with constipation, and have the potential to worsen or trigger central sleep apnoea (<LINK REF="REF-Randerath-2012" TYPE="REFERENCE">Randerath 2012</LINK>). In this regard, it should be noted that only one patient had withdrawal symptoms after 12 weeks in the <LINK REF="STD-Trenkwalder-2013" TYPE="STUDY">Trenkwalder 2013</LINK> study.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-06-08 03:02:34 +0100" MODIFIED_BY="[Empty name]">
<P>This review included only one study (<LINK REF="STD-Trenkwalder-2013" TYPE="STUDY">Trenkwalder 2013</LINK>; N = 304), in which patients for whom previous treatment had failed were given oxycodone/naloxone twice daily at a mean dose of 20 mg oxycodone and 10 mg naloxone. The intervention was effective in relieving symptoms and improving quality of life, which are the most important outcomes when treating patients with RLS, measured according to the Clinical Global Impression scale and RLS Quality of Life questionnaire (RLS-QoL). Although patients reduced RLS symptoms score at the end of the treatment compared to the placebo group, the authors did not report the minimum clinically important change to be expected for the IRLSSS. <LINK REF="STD-Trenkwalder-2013" TYPE="STUDY">Trenkwalder 2013</LINK> did not address polysomnographic variables such as total sleep time or periodic leg movement in sleep. The authors carefully screened patients, excluding those with secondary RLS, those taking dopamine receptor blockers, those with co-morbidities (apnoea syndrome, narcolepsy, myoclonus epilepsy, hallucinations or psychotic episodes, acute clinical augmentation, clinically evident respiratory disorders, clinically relevant constipation, or ileus), previous treatment with naloxone or naltrexone within 30 days of entry, contraindications or hypersensitivity to oxycodone, naloxone, related products, or other ingredients, drugs that potentially affected sleep architecture or motor manifestations during sleep, CNS depressants, current alcohol or drug misuse (including opioids), taking an investigational drug within 30 days of study entry, or taking monoamine oxidase inhibitors within two weeks of screening. Shift workers and patients with serum ferritin below 30 &#956;g/L at screening were also excluded. Pregnant women were also not included, although this was not stated in the published text. All these restriction reflect the current caution towards the use of opioids to treat RLS symptoms, mostly derived from the medical experience of using opioids in the treatment of pain-related syndromes. On the other hand, physicians should bear in mind that the external validity of oxycodone/naloxone treatment for RLS could be an issue in this review.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-07-06 00:12:09 +0100" MODIFIED_BY="[Empty name]">
<P>The conclusions of this review are based on a single study of low evidence quality (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>, <LINK REF="STD-Trenkwalder-2013" TYPE="STUDY">Trenkwalder 2013</LINK>), which was well-designed and performed overall. This study was downgraded to a low evidence quality because of high attrition bias. As stated above, this study had a large number of dropouts before the planned 12 weeks of treatment, and thus may have underestimated the occurrence of adverse events (attrition bias), including potentially serious adverse events; this, however, may have been minimized by the use of intention-to-treat analysis (ITT). External validity is also an issue in this review, since the included study addressed patients with moderate or severe RLS in whom previous treatment had failed. Although the ITT analysis favours their conclusions about the benefits of the intervention, the high attrition bias precludes prediction of the entire range of possible adverse events for the oxycodone/naloxone treatment, which is an important issue when we are using opioids.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]">
<P>It is always possible that some clinical trials were performed and not published, published locally (e.g., as theses or dissertations), or in languages not included in the search strategy. Another potential source of bias was that we could not include three cross-over studies, since the primary data required for standard analysis were not available (<LINK REF="STD-Allen-1992" TYPE="STUDY">Allen 1992</LINK>; <LINK REF="STD-Kaplan-1993" TYPE="STUDY">Kaplan 1993</LINK>; <LINK REF="STD-Walters-1993" TYPE="STUDY">Walters 1993</LINK>).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]">
<P>This systematic review suggests that opioids seem to be effective in the treatment of RLS. This finding is supported by one, multicentre trial (<LINK REF="STD-Trenkwalder-2013" TYPE="STUDY">Trenkwalder 2013</LINK>; N = 304), confirming what has been suggested by previous small, randomised, double-blind, cross-over studies (<LINK REF="STD-Allen-1992" TYPE="STUDY">Allen 1992</LINK>; <LINK REF="STD-Kaplan-1993" TYPE="STUDY">Kaplan 1993</LINK>; <LINK REF="STD-Walters-1993" TYPE="STUDY">Walters 1993</LINK>). Compared to this study, other available systematic reviews do not add further information, since they were based on those three small trials that we excluded from this review for methodological reasons (<LINK REF="REF-Hornyak-2014" TYPE="REFERENCE">Hornyak 2014</LINK>; <LINK REF="REF-Wilt-2012" TYPE="REFERENCE">Wilt 2012</LINK>; <LINK REF="REF-Wilt-2013" TYPE="REFERENCE">Wilt 2013</LINK>.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-07-06 00:04:57 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-07-06 00:04:57 +0100" MODIFIED_BY="[Empty name]">
<P>This systematic review found low evidence, based on one trial, in favour of prolonged release oxycodone/naloxone to treat RLS symptoms in patients who had failed previous treatment. The benefits of opioids included amelioration of subjective RLS symptoms and improved quality of life. Adverse events were common during opioid treatment. They were mostly mild to moderate in severity and included gastrointestinal complaints (obstipation, ileus, sub-ileus, nausea, vomiting, flank pain), fatigue, headache, somnolence, dizziness, dry mouth, and pruritus. Withdrawal symptoms were also reported.</P>
<P>Further large, well-designed, randomised clinical trials, that address issues such as minimal clinically important change in RSL symptoms, adverse events, and respiratory polysomnographic data, are still required before clinicians should consider prescribing opioids to treat symptoms of RLS.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]">
<P>Many opioid drugs are available to use in RLS, and it would be of interest to perform randomised clinical trial to assess the effect of these agents in this very distressing condition. Even though opioids have demonstrated effectiveness for the treatment of RLS symptoms, this drug class still has to be compared to other agents recommended for RLS. Furthermore, the impact of opioid treatment on sleep variables as assessed by polysomnography should be evaluated.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-08-07 22:50:32 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank the authors who sent supplemental information about their studies and thus allowed us to perform a better classification of these publications. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-10-18 17:18:57 +0100" MODIFIED_BY="[Empty name]">
<P>None known for all authors.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]">
<P>César Osório: Literature search, data extraction, drafting of written submissions.</P>
<P>Luciane Bizari Coin de Carvalho: study selection, data extraction, statistical analysis, development of final review.</P>
<P>Karla Carlos: study selection, data extraction, statistical analysis, development of final review.</P>
<P>Cristiane Fiquene Conti : Protocol development, literature search.</P>
<P>Marcio Moyses de Oliveira : Protocol development, literature search.</P>
<P>Lucila Bizari Fernandes do Prado: study selection, data extraction, statistical analysis, development of final review.</P>
<P>Gilmar Fernandes do Prado : Protocol development, literature search, study selection, data extraction, statistical analysis, development of final review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-06-24 13:57:45 +0100" MODIFIED_BY="[Empty name]">
<P>None.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2013-11-21 20:36:32 +0000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-08-19 11:46:53 +0100" MODIFIED_BY="Ema Roque">
<STUDIES MODIFIED="2016-06-22 20:17:59 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-05-26 15:00:26 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Trenkwalder-2013" MODIFIED="2016-05-26 15:00:26 +0100" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-05-26 15:00:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Benes H, Grote L, Garcia-Borreguero D, Hogl B, Hopp M, et al</AU>
<TI>Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension</TI>
<SO>Lancet Neurology</SO>
<YR>2013</YR>
<VL>pii: S1474-4422</VL>
<NO>13</NO>
<PG>70239-4</PG>
<IDENTIFIERS MODIFIED="2013-10-27 17:59:29 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4298476"/><IDENTIFIER MODIFIED="2013-10-27 17:59:29 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S1474-4422(13)70239-4"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2813508"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-06-22 20:17:59 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-1992" MODIFIED="2016-06-22 20:17:34 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-06-22 20:17:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP, Kaplan PW, Buchholz DW, Earley CJ, Walters JK</AU>
<TI>Double-blinded, placebo controlled comparison of high dose propoxyphene and moderate carbidopa/levodopa for treatment of periodic limb movements in sleep</TI>
<SO>Sleep Research</SO>
<YR>1992</YR>
<VL>21</VL>
<PG>166</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4298477"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2813510"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaplan-1993" MODIFIED="2016-06-22 20:17:49 +0100" MODIFIED_BY="[Empty name]" NAME="Kaplan 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-06-22 20:17:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP, Kaplan PW, Buchholz DW, Walters JK</AU>
<TI>Double-blinded, placebo controlled comparison of propoxyphene and carbidopa/levodopa for treatment of periodic limb movements in sleep</TI>
<SO>Sleep Research</SO>
<YR>1991</YR>
<VL>20</VL>
<PG>199</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4298478"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-06-22 20:17:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan PW, Allen RP, Buchholz DW, Walters JK</AU>
<TI>A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene</TI>
<SO>Sleep</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>8</NO>
<PG>717-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4298479"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2813512"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walters-1993" MODIFIED="2016-06-22 20:17:59 +0100" MODIFIED_BY="[Empty name]" NAME="Walters 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-06-22 20:17:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty S, et al</AU>
<TI>Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo</TI>
<SO>Sleep</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>4</NO>
<PG>327-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4298480"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2813515"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-08-01 12:13:07 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-06-22 20:18:32 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-06-22 20:18:32 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Allen-2001" MODIFIED="2016-06-08 02:55:26 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP, Earley CJ</AU>
<TI>Validation of Johns Hopkins restless legs severity scale</TI>
<SO>Sleep Medicine</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>3</NO>
<PG>239-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-2003" MODIFIED="2016-05-26 15:14:36 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J, et al</AU>
<TI>Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health</TI>
<SO>Sleep Medicine</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>2</NO>
<PG>101-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-2004" MODIFIED="2016-05-26 15:15:02 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP</AU>
<TI>Dopamine and iron in the pathophysiology of restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2004</YR>
<VL>5</VL>
<PG>385-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-2013" MODIFIED="2016-05-26 15:15:46 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 2013" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP, Auerbach S, Bahrain H, Auerbach M, Earley CJ</AU>
<TI>The prevalence and impact of restless legs syndrome on patients with iron deficiency anaemia</TI>
<SO>American Journal of Hematology</SO>
<YR>2013</YR>
<VL>88</VL>
<NO>4</NO>
<PG>261&#8211;4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aurora-2012" MODIFIED="2013-10-16 23:31:14 +0100" MODIFIED_BY="[Empty name]" NAME="Aurora 2012" TYPE="JOURNAL_ARTICLE">
<AU>Aurora RN, Kristo DA, Bista SR, Rowley JA, Zak RS, Casey KR, et al</AU>
<TI>The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline</TI>
<SO>Sleep</SO>
<YR>2012</YR>
<VL>35</VL>
<NO>8</NO>
<PG>1039-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1988" MODIFIED="2016-06-08 02:49:11 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen 1988" TYPE="BOOK">
<AU>Cohen J</AU>
<TI>
<I>Statistical Power Analysis in the Sciences</I>
</TI>
<SO>Statistical Power Analysis in the Sciences</SO>
<YR>1988</YR>
<EN>2nd</EN>
<PB>Lawrence Erlbaum Associates, Inc.</PB>
<CY>Hillsdale (NJ)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeAndrade-2013" MODIFIED="2016-06-08 02:57:29 +0100" MODIFIED_BY="[Empty name]" NAME="DeAndrade 2013" TYPE="JOURNAL_ARTICLE">
<AU>DeAndrade MP, Unger EL, Zhang L, Yokoi F, Walters AS, Li Y</AU>
<TI>Hyperactivityand alterations in iron homeostasis in mu opioid receptor knockout mice: possible implications for restless legs syndrome/Willis-Ekbom disease</TI>
<SO>Sleep Medicine</SO>
<YR>2013</YR>
<VL>14S</VL>
<PG>e41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Earley-2013" MODIFIED="2013-10-16 23:06:13 +0100" MODIFIED_BY="[Empty name]" NAME="Earley 2013" TYPE="JOURNAL_ARTICLE">
<AU>Earley CJ, Kuwabara H, Wong DF, Gamaldo C, Salas RE, Bra&#353;i&#263; JR, et al</AU>
<TI>Increased synaptic dopamine in the putamen in restless legs syndrome</TI>
<SO>Sleep</SO>
<YR>2013</YR>
<VL>36</VL>
<NO>1</NO>
<PG>51-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Earley-2014" MODIFIED="2016-06-08 02:49:34 +0100" MODIFIED_BY="[Empty name]" NAME="Earley 2014" TYPE="JOURNAL_ARTICLE">
<AU>Earley CJ, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee PC, et al</AU>
<TI>Altered brain iron homeostasis and dopaminergic function in restless legs syndrome (Willis-Ekbom disease)</TI>
<SO>Sleep Medicine</SO>
<YR>2014</YR>
<VL>15</VL>
<NO>11</NO>
<PG>1288-301</PG>
<IDENTIFIERS MODIFIED="2016-05-26 15:45:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-05-26 15:45:44 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="http://dx.doi.org/doi:10.1016/j.sleep.2014.05.009"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Borreguero-2013" MODIFIED="2016-05-26 15:47:53 +0100" MODIFIED_BY="[Empty name]" NAME="Garcia-Borreguero 2013" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B, et al</AU>
<TI>The long-term treatment of restless legs syndrome/Willis&#8211;Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group</TI>
<SO>Sleep Medicine</SO>
<YR>2013</YR>
<VL>14</VL>
<NO>7</NO>
<PG>675&#8211;84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-2014" MODIFIED="2016-06-08 02:49:54 +0100" MODIFIED_BY="[Empty name]" NAME="GRADEpro 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro</TI>
<YR>2014</YR>
<EN>accessed April 2016</EN>
<PB>McMaster University</PB>
<CY>Hamilton</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hening-1986" MODIFIED="2016-06-08 02:56:13 +0100" MODIFIED_BY="[Empty name]" NAME="Hening 1986" TYPE="JOURNAL_ARTICLE">
<AU>Hening WA, Walters A, Kavey N, Gidro-Frank S, Cote L, Fahn S</AU>
<TI>Dyskinesias while awake and periodic movements in sleep in restless legs syndrome:treatment with opioids</TI>
<SO>Neurology</SO>
<YR>1986</YR>
<VL>36</VL>
<PG>1363&#8211;66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-06-08 02:48:44 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from: www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hornyak-2006" MODIFIED="2016-05-26 15:49:04 +0100" MODIFIED_BY="[Empty name]" NAME="Hornyak 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hornyak M, Feige B, Riemann D, Voderholzer U</AU>
<TI>Periodic leg movements in sleep and periodic limb movement disorder: Prevalence, clinical significance and treatment</TI>
<SO>Sleep Medicine Reviews</SO>
<YR>2006</YR>
<VL>10</VL>
<PG>169&#8211;77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hornyak-2014" MODIFIED="2016-06-08 02:55:58 +0100" MODIFIED_BY="[Empty name]" NAME="Hornyak 2014" TYPE="JOURNAL_ARTICLE">
<AU>Hornyak M, Scholz H, Kohnen R, Bengel J, Kassubek J, Trenkwalder C</AU>
<TI>What treatment works best for restless legs syndrome? Meta&#8208;analyses of dopaminergic and non&#8208;dopaminergic medications</TI>
<SO>Sleep Medicine Reviews</SO>
<YR>2014</YR>
<VL>18</VL>
<NO>2</NO>
<PG>153-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICSD-2014" MODIFIED="2016-06-22 20:18:32 +0100" MODIFIED_BY="[Empty name]" NAME="ICSD 2014" TYPE="BOOK">
<AU>American Academy of Sleep Medicine</AU>
<SO>There is also The International Classification of Sleep Disorders &#8211; Third Edition (ICSD-3)</SO>
<YR>2014</YR>
<EN>3rd</EN>
<PB>American Academy of Sleep Medicine</PB>
<CY>Darien</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-IRLSSG-2003" MODIFIED="2016-06-08 02:50:27 +0100" MODIFIED_BY="[Empty name]" NAME="IRLSSG 2003" TYPE="JOURNAL_ARTICLE">
<AU>Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al, The International Restless Legs Syndrome Study Group</AU>
<TI>Validation of The International Restless Legs Syndrome Study Group rating scale for restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>2</NO>
<PG>121-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2001" MODIFIED="2016-06-08 02:51:10 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 2001" TYPE="JOURNAL_ARTICLE">
<AU>Lee KA, Zaffke ME, Baratte B</AU>
<TI>Restless legs syndrome and sleep disturbance during pregnancy: the role of folate and iron</TI>
<SO>Journal of Women's Health &amp; Gender-based Medicine</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>4</NO>
<PG>335-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mizoguchi-2014" MODIFIED="2016-06-08 02:51:32 +0100" MODIFIED_BY="[Empty name]" NAME="Mizoguchi 2014" TYPE="JOURNAL_ARTICLE">
<AU>Mizoguchi H, Takagi H, Watanabe C, Yonezawa A, Sato T, Sakurada T, et al</AU>
<TI>Involvement of multiple-opioid receptor subtypes on the presynaptic or postsynaptic inhibition of spinal pain transmission</TI>
<SO>Peptides</SO>
<YR>2014</YR>
<VL>51</VL>
<PG>15-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohayon-2002" MODIFIED="2016-05-26 16:02:10 +0100" MODIFIED_BY="[Empty name]" NAME="Ohayon 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ohayon MM, Roth T</AU>
<TI>Prevalence of restless legs syndrome and periodic limb movements disorder in the general population</TI>
<SO>Journal of Psychosomatic Research</SO>
<YR>2002</YR>
<VL>53</VL>
<PG>547-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohayon-2012" MODIFIED="2016-05-26 16:03:04 +0100" MODIFIED_BY="[Empty name]" NAME="Ohayon 2012" TYPE="JOURNAL_ARTICLE">
<AU>Ohayon MM, O'Hara R, Vitiello MV</AU>
<TI>Epidemiology of restless legs syndrome: a synthesis of the literature</TI>
<SO>Sleep Medicine Reviews</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>4</NO>
<PG>283&#8211;95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Picchietti-2005" MODIFIED="2016-06-08 02:51:49 +0100" MODIFIED_BY="[Empty name]" NAME="Picchietti 2005" TYPE="JOURNAL_ARTICLE">
<AU>Picchietti D, Winkelman JW</AU>
<TI>Restless legs syndrome, periodic limb movements in sleep, and depression</TI>
<SO>Sleep</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>7</NO>
<PG>891-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Picchietti-2007" MODIFIED="2013-11-21 20:39:56 +0000" MODIFIED_BY="[Empty name]" NAME="Picchietti 2007" TYPE="JOURNAL_ARTICLE">
<AU>Picchietti D, Allen RP, Walters AS, Davidson JE, Myers A</AU>
<TI>Restless legs syndrome: prevalence and impact in children and adolescents&#8212;the Peds REST study</TI>
<SO>Pediatrics</SO>
<YR>2007</YR>
<VL>120</VL>
<NO>2</NO>
<PG>253&#8211;66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Randerath-2012" MODIFIED="2016-05-26 16:04:23 +0100" MODIFIED_BY="[Empty name]" NAME="Randerath 2012" TYPE="JOURNAL_ARTICLE">
<AU>Randerath WJ, George S</AU>
<TI>Opioid-induced sleep apnea: is it a real problem?</TI>
<SO>Journal of Clinical Sleep Medicine</SO>
<YR>2012</YR>
<VL>8</VL>
<NO>5</NO>
<PG>577-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-06-08 02:52:05 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rizzo-2013" MODIFIED="2016-06-08 02:57:00 +0100" MODIFIED_BY="[Empty name]" NAME="Rizzo 2013" TYPE="JOURNAL_ARTICLE">
<AU>Rizzo G, Manners D, Testa C, Tonon C, Vetrugno R, Marconi S, et al</AU>
<TI>Low brain iron content in idiopathic restless legs syndrome patients detected by phase imaging</TI>
<SO>Movement Disorders</SO>
<YR>2013</YR>
<VL>28</VL>
<NO>13</NO>
<PG>1886-90</PG>
<IDENTIFIERS MODIFIED="2016-05-26 16:05:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-05-26 16:05:19 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="doi: 10.1002/mds.25576"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rye-2012" MODIFIED="2016-06-08 02:52:34 +0100" MODIFIED_BY="[Empty name]" NAME="Rye 2012" TYPE="JOURNAL_ARTICLE">
<AU>Rye DB, Trotti LM</AU>
<TI>Restless legs syndrome and periodic leg movements of sleep</TI>
<SO>Neurologic Clinics</SO>
<YR>2012</YR>
<VL>30</VL>
<PG>1137-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandyk-1987" MODIFIED="2016-06-08 02:52:52 +0100" MODIFIED_BY="[Empty name]" NAME="Sandyk 1987" TYPE="JOURNAL_ARTICLE">
<AU>Sandyk R, BamfordCR, Gillman MA</AU>
<TI>Opiates in the restless legs syndrome</TI>
<SO>International Journal of Neuroscience</SO>
<YR>1987</YR>
<VL>36</VL>
<PG>99-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silver-2011" MODIFIED="2016-05-26 16:09:25 +0100" MODIFIED_BY="[Empty name]" NAME="Silver 2011" TYPE="JOURNAL_ARTICLE">
<AU>Silver N, Allen RP, Senerth J, Earley CJ</AU>
<TI>A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2011</YR>
<VL>12</VL>
<PG>440-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trenkwalder-2005" MODIFIED="2016-06-08 02:53:07 +0100" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2005" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Paulus W, Walters AS</AU>
<TI>The restless legs syndrome review</TI>
<SO>Lancet Neurology</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>8</NO>
<PG>465-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-1995" MODIFIED="2016-06-08 02:53:22 +0100" MODIFIED_BY="[Empty name]" NAME="Walters 1995" TYPE="JOURNAL_ARTICLE">
<AU>Walters A</AU>
<TI>Towards a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group.</TI>
<SO>Movement Disorders</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>5</NO>
<PG>634-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-2001" MODIFIED="2016-05-26 16:15:32 +0100" MODIFIED_BY="[Empty name]" NAME="Walters 2001" TYPE="JOURNAL_ARTICLE">
<AU>Walters AS, Winkelmann J, Trenkwalder C, Fry JM, Kataria V, Wagner M, et al</AU>
<TI>Long-term follow-up on restless legs syndrome patients treated with opioids</TI>
<SO>Movement Disorders</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>6</NO>
<PG>1105-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-2009" MODIFIED="2016-06-08 02:53:37 +0100" MODIFIED_BY="[Empty name]" NAME="Walters 2009" TYPE="JOURNAL_ARTICLE">
<AU>Walters AS, Ondo WG, Zhu W, Le W</AU>
<TI>Does the endogenous opiate system play a role in the restless legs syndrome? A pilot post-mortem study</TI>
<SO>Journal of Neurological Sciences</SO>
<YR>2009</YR>
<VL>279</VL>
<PG>62&#8211;5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetter-2004" MODIFIED="2016-05-26 16:18:23 +0100" MODIFIED_BY="[Empty name]" NAME="Wetter 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wetter TC, Eisenensehr I,Trenkwalder C</AU>
<TI>Functional neuroimaging studies in restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2004</YR>
<VL>5</VL>
<PG>401-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilt-2012" MODIFIED="2016-06-08 02:53:56 +0100" MODIFIED_BY="[Empty name]" NAME="Wilt 2012" TYPE="BOOK">
<AU>Wilt TJ, MacDonald R, Ouellette J, Tacklind J, Khawaja I, Rutks I, et al</AU>
<SO>Treatment for restless legs syndrome. (Comparative Effectiveness Reviews, No. 86.)</SO>
<YR>2012</YR>
<PB>Agency for Healthcare Research and Quality (US); Report No.: 12(13)-EHC147-EF. Available from: http://www.ncbi.nlm.nih.gov/books/NBK115378/</PB>
<CY>Rockville (MD)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilt-2013" MODIFIED="2016-06-08 02:54:15 +0100" MODIFIED_BY="[Empty name]" NAME="Wilt 2013" TYPE="JOURNAL_ARTICLE">
<AU>Wilt TJ, MacDonald R, Ouellette J, Khawaja IS, Rutks I, Butler M, et al</AU>
<TI>Pharmacologic therapy for primary restless legs syndrome: a systematic review and meta&#8208;analysis</TI>
<SO>JAMA internal medicine</SO>
<YR>2013</YR>
<VL>173</VL>
<NO>7</NO>
<PG>496-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winkelmann-2002" MODIFIED="2016-06-08 02:54:34 +0100" MODIFIED_BY="[Empty name]" NAME="Winkelmann 2002" TYPE="JOURNAL_ARTICLE">
<AU>Winkelmann J, Stautner A, Samtleben W, Trankwalder C W</AU>
<TI>Long-term course of restless legs syndrome in dialysis patients after kidney transplantation of restless legs syndrome in dialysis patients</TI>
<SO>Movement Disorders</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>5</NO>
<PG>1072-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yeh-2012" MODIFIED="2016-06-08 02:55:01 +0100" MODIFIED_BY="[Empty name]" NAME="Yeh 2012" TYPE="JOURNAL_ARTICLE">
<AU>Yeh P, Walters AS, Tsuang JW</AU>
<TI>Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment</TI>
<SO>Sleep and Breathing</SO>
<YR>2012</YR>
<VL>16</VL>
<PG>987&#8211;1007</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-06-08 03:01:50 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-06-08 03:01:50 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-06-08 03:01:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trenkwalder-2013">
<CHAR_METHODS MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>Analysis: RLS treatment with prolonged release oxycodone/naloxone or placebo</P>
<P>Treatment duration: 12 weeks (blinding phase)<BR/>Follow-up: 40 weeks (open label)<BR/>Center: Multicentre study conducted at 55 sites in Austria, Germany, Spain, and Sweden</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]">
<P>N = 304</P>
<P>Drop out in the first week = 28</P>
<P>Drop out up to the 12th week = 130</P>
<P>Oxycodone/naloxone group (safety population) = 132</P>
<P>Placebo group (safety population) = 144</P>
<P>Diagnosis: presence of the four classic symptoms of RLS for at least 6 months, failed treatment of symptoms, and no regular intake of opioid-containing drugs at any time before enrolment.</P>
<P>Exclusions: secondary RLS or RLS associated with previous or concomitant dopamine receptor blocking drugs, history or presence of sleep apnoea syndrome, narcolepsy, myoclonus epilepsy, hallucinations or psychotic episodes, acute clinical augmentation according to Max Planck Institute diagnostic criteria, treatment with naloxone or naltrexone within 30 days of study entry, and a contraindication or hypersensitivity to oxycodone, naloxone, related products, or other ingredients, evident respiratory disorders, clinically relevant constipation, or ileus, drugs likely to have affected sleep architecture or motor manifestations during sleep or other CNS depressants, current alcohol or drug misuse, history of opioid misuse, taking an investigational drug within 30 days of study entry, serum ferritin less than 30 &#956;g/L at screening, having taken monoamine oxidase inhibitors within 2 weeks of screening. Stable non-opioid analgesic regimens prescribed for reasons other than RLS could be continued during the study.</P>
<P>Gender: 202 female, 104 male<BR/>Race: 99% white in the drug group and 100% white in the placebo group</P>
<P>Age: Drug group, mean age 63.1 ± 11.4 years; Placebo Group, mean age 61.7 ± 11.0 years.</P>
<P>Setting: 55 hospitals and specialised private neurology practices sites in Austria, Germany, Spain, and Sweden</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]">
<P>Group 1: oxycodone (N = 132)</P>
<P>Group 2: placebo (N = 144)</P>
<P>Group 1 treatment schedule: prolonged release oxycodone/naloxone up-titrated during the first 6 weeks to the best dose (maximum oxycodone 40 mg, naloxone 20 mg, twice daily)</P>
<P>Group 2 treatment schedule: matching placebo tablets (identical in appearance, colour, and taste).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-08 03:01:50 +0100" MODIFIED_BY="[Empty name]">
<P>International Restless Legs Syndrome Severety Scale (IRLSSS,ranging from 0 to 40): change from baseline difference between drug and placebo.<BR/>Clinical Global Impression (CGI): severity (item 1) and assessment of therapeutic effect (item 3)</P>
<P>Resltess Legs Syndrome Quality of Life questionnaire (RLS-QoL): quality of life specific for this disease, 12-point rating scale ranging from 0 to 4.</P>
<P>RLS-6 scores: symptom severity at different times during day and night; data not shown</P>
<P>RLS leg or arm pain score (numerical, 11-point rating scale ranging from 0 to 10)</P>
<P>Proportion of treatment responders and remitters on the IRLSSS and CGI scales</P>
<P>Augmentation: patients who reported worsening disease were assessed for augmentation with the Max Planck Institute diagnostic criteria.</P>
<P>Adverse events: premature study discontinuation because of adverse events, changes in clinical laboratory parameters, vital signs, 12-lead electrocardiogram, physical examinations, or CGI-4 score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]">
<P>Funding and other possible conflicts: Mundipharma Research. The sponsor also proposed the idea for this study and took part in all stages of research. According to the authors, the sponsor allowed access to all data, and interpretation of said data and the published text were under their responsibility. The article was prepared by the authors with the support of a medical writer paid for by the sponsor.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-06-08 02:47:25 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allen-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]">
<P>There was no information about the washout period; the data were not provided for each period; we were unable to analyse the variance or to use the first period data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-08 02:47:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaplan-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-08 02:47:25 +0100" MODIFIED_BY="[Empty name]">
<P>There was no information about the washout period; the data were not provided for each period; we were unable to analyse the variance or to use the first period data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-08 02:47:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Walters-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-08 02:47:25 +0100" MODIFIED_BY="[Empty name]">
<P>There was no information about the washout period; the data were not provided for each period; we were unable to analyse the variance or to use the first period data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-08-01 12:13:07 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2013">
<DESCRIPTION>
<P>Random allocation sequences were generated by the sponsor and checked for accuracy by an unmasked statistician who had no other role in the study. Treatment allocations were not made available until the study was completed and after the final clinical database lock, except in the case of an emergency.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2013">
<DESCRIPTION>
<P>Randomisation with a validated interactive response technology system that automated the random assignment of treatment groups to randomisation<BR/>numbers by site in blocks of four.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-08-01 15:46:12 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-08-01 15:46:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2013">
<DESCRIPTION>
<P>Matching placebo tablets (identical in appearance, colour, and taste).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-04-28 13:04:13 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-27 18:33:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2013">
<DESCRIPTION>
<P>During the double-blind phase, patients and all personnel involved in the conduct and interpretation of the study (including investigators, site personnel, and sponsor staff) were masked to treatment assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Trenkwalder-2013">
<DESCRIPTION>
<P>A total of 306 patients was randomised and 174 completed the study; intention-to-treat analysis was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2013">
<DESCRIPTION>
<P>All relevant clinical outcome were analysed; no subgroup analysis was performed. Supplementary data were also available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-08 02:47:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trenkwalder-2013">
<DESCRIPTION>
<P>Study was proposed by Mundipharma and the Primary Investigator and more two investigators declared conflict of interest with this pharmaceutical company.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-08-17 14:33:15 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-08-17 14:33:15 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-08-17 14:32:31 +0100" MODIFIED_BY="GDT">Opioids compared to placebo for RLS</TITLE>
<TABLE COLS="7" ROWS="15">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Opioid treatment compared to placebo for patients with RLS</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>RLS<BR/>
<B>Setting: </B>55 hospitals and specialised private neurology practices in Austria, Germany, Spain, and Sweden.<BR/>
<B>Intervention: </B>opioids<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8470; of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with opioids</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>RLS symptoms<BR/>assessed with: IRLSSS<BR/>Scale from: 0 to 40<BR/>follow up: mean 12 weeks</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean RLS symptoms was 22.1 points</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean RLS symptoms in the intervention group was 7 points lower (9,69 lower to 4,31 lower)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>270<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Moderate effect size of difference in mean response (0.57) <SUP>2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>RLS symptoms<BR/>assessed with: CGI<BR/>Scale from: 0 to 7<BR/>follow up: mean 12 weeks</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean RLS symptoms was 4.1 points</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean RLS symptoms in the intervention group was 1,11 points lower (1,49 lower to 0,73 lower)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>276<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Moderate effect size of difference in mean response (0.64) <SUP>2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Drug responders<BR/>assessed with: IRLSSS - Reduced score at least 50%<BR/>follow up: mean 12 days</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.82<BR/>(1.37 to 2.42)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>276<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>313 per 1.000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>569 per 1.000<BR/>(428 to 756)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Drug responders<BR/>assessed with: CGI - Self reported "Much improved" or "Very much improved"<BR/>follow up: mean 12 weeks</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.92<BR/>(1.49 to 2.48)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>276<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>347 per 1.000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>667 per 1.000<BR/>(517 to 861)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Remitters<BR/>assessed with: IRLSSS - Scored 10 or less<BR/>follow up: mean 12 weeks</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 2.14<BR/>(1.45 to 3.16)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>276<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>194 per 1.000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>416 per 1.000<BR/>(282 to 614)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Adverse Events<BR/>assessed with: clinical assessment<BR/>follow up: mean 12 weeks</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.22<BR/>(1.07 to 1.39)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>304<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>688 per 1.000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>840 per 1.000<BR/>(736 to 957)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Quality of life<BR/>assessed with: RLS Quality of Life Questionnaire (RLS-QoL)<BR/>Scale from: 0 to 7<BR/>follow up: mean 12 weeks</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean quality of life was 3.64 points</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>The mean quality of life in the intervention group was 0,73 points lower (1,1 lower to 0,36 lower)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>276<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Small effect size of difference in mean response (0.43) <SUP>2</SUP>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> The only trial included presentes high risk of attrition bias.</P>
<P>
<SUP>2</SUP> 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect of difference in mean response (Cohen 1988).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-04-02 12:35:26 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-05-26 04:45:55 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-05-26 04:45:55 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>opioids and placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-4.3091877004782955" CI_START="-9.690812299521708" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.000000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2016-05-26 04:38:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="3.419247763322169E-7" Q="0.0" RANDOM="YES" SCALE="29.49707981168839" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="144" UNITS="" WEIGHT="100.0" Z="5.098738360241284">
<NAME>RLS symptoms - IRLSSS</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [opiod]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.3091877004782955" CI_START="-9.690812299521708" EFFECT_SIZE="-7.000000000000002" ESTIMABLE="YES" MEAN_1="15.1" MEAN_2="22.1" MODIFIED="2014-04-01 12:46:33 +0100" MODIFIED_BY="[Empty name]" ORDER="50" SD_1="10.6" SD_2="12.2" SE="1.3728886452743472" STUDY_ID="STD-Trenkwalder-2013" TOTAL_1="132" TOTAL_2="144" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.7335022469753203" CI_START="-1.4864977530246786" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1099999999999994" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2016-05-26 04:45:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="7.540790979851464E-9" Q="0.0" RANDOM="NO" SCALE="3.4664124269973295" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="144" UNITS="" WEIGHT="100.0" Z="5.778414360674425">
<NAME>RLS symptoms - CGI</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [opioid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.7335022469753203" CI_START="-1.4864977530246786" EFFECT_SIZE="-1.1099999999999994" ESTIMABLE="YES" MEAN_1="2.99" MEAN_2="4.1" MODIFIED="2016-04-13 11:59:43 +0100" MODIFIED_BY="[Empty name]" ORDER="6" SD_1="1.48" SD_2="1.71" SE="0.19209422009508614" STUDY_ID="STD-Trenkwalder-2013" TOTAL_1="132" TOTAL_2="144" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.859636075696291E-31" CI_END="2.415972129574664" CI_START="1.3683043291351757" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8181818181818183" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="45" I2="100.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.38309191999804015" LOG_CI_START="0.13618270101347218" LOG_EFFECT_SIZE="0.25963731050575617" METHOD="MH" MODIFIED="2016-05-26 04:45:55 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="3.7559882168928866E-5" Q="0.0" RANDOM="NO" SCALE="5.00897400251545" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="144" WEIGHT="100.00000000000001" Z="4.121999006168584">
<NAME>Drug responders - IRLSSS</NAME>
<GROUP_LABEL_1>Opiod</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [placebo]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [opiod]</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.415972129574664" CI_START="1.3683043291351757" EFFECT_SIZE="1.8181818181818181" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="45" LOG_CI_END="0.38309191999804015" LOG_CI_START="0.13618270101347218" LOG_EFFECT_SIZE="0.2596373105057561" MODIFIED="2014-04-01 12:48:19 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.1450356974518809" STUDY_ID="STD-Trenkwalder-2013" TOTAL_1="132" TOTAL_2="144" VAR="0.021035353535353535" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.317956298433299E-31" CI_END="2.4761222718877853" CI_START="1.4887794685476106" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9199999999999997" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="50" I2="100.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.3937720865092421" LOG_CI_START="0.17283037089785697" LOG_EFFECT_SIZE="0.28330122870354957" METHOD="MH" MODIFIED="2016-04-13 12:18:10 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="5.000208906361262E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="144" WEIGHT="100.0" Z="5.026304819788313">
<NAME>Drug responders - CGI</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [placebo]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [opioid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4761222718877858" CI_START="1.4887794685476106" EFFECT_SIZE="1.92" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="50" LOG_CI_END="0.3937720865092422" LOG_CI_START="0.17283037089785697" LOG_EFFECT_SIZE="0.28330122870354957" MODIFIED="2016-04-13 12:18:10 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.12978225742925859" STUDY_ID="STD-Trenkwalder-2013" TOTAL_1="132" TOTAL_2="144" VAR="0.016843434343434344" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.1615512283494236" CI_START="1.4523999148010562" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="28" I2="0.0" I2_Q="100.0" ID="CMP-001.05" LOG_CI_END="0.49990022331805595" LOG_CI_START="0.16208621476479287" LOG_EFFECT_SIZE="0.3309932190414244" METHOD="MH" MODIFIED="2016-04-13 12:09:44 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="1.2264356522466386E-4" Q="3.130328718038028E-31" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="144" WEIGHT="100.0" Z="3.8407808558707726">
<NAME>Remitters - IRLSSS</NAME>
<GROUP_LABEL_1>opiod</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [placebo]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [opioid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.161551228349423" CI_START="1.4523999148010565" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="28" LOG_CI_END="0.4999002233180559" LOG_CI_START="0.16208621476479293" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2014-04-01 12:49:48 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.19843362083049804" STUDY_ID="STD-Trenkwalder-2013" TOTAL_1="132" TOTAL_2="144" VAR="0.03937590187590187" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.33018286609506786" CI_START="-1.1498171339049326" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7400000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2016-05-26 04:40:35 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="4.01532588458315E-4" Q="0.0" RANDOM="NO" SCALE="7.7239665777456175" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="144" UNITS="" WEIGHT="100.0" Z="3.5390744519141846">
<NAME>Sleep adequacy - MOS</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [opioid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.33018286609506786" CI_START="-1.1498171339049326" EFFECT_SIZE="-0.7400000000000002" ESTIMABLE="YES" MEAN_1="3.29" MEAN_2="4.03" MODIFIED="2016-04-13 12:00:52 +0100" MODIFIED_BY="[Empty name]" ORDER="9" SD_1="1.74" SD_2="1.73" SE="0.20909421659658933" STUDY_ID="STD-Trenkwalder-2013" TOTAL_1="132" TOTAL_2="144" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.2562137434806162" CI_START="0.5237862565193832" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8899999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2016-05-26 04:40:38 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="1.9049872765380446E-6" Q="0.0" RANDOM="NO" SCALE="15.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="144" UNITS="" WEIGHT="100.0" Z="4.7632509082308">
<NAME>Sleep quantity - MOS</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [placebo]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [opioid]</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2562137434806162" CI_START="0.5237862565193832" EFFECT_SIZE="0.8899999999999997" ESTIMABLE="YES" MEAN_1="6.25" MEAN_2="5.36" MODIFIED="2016-04-13 12:01:48 +0100" MODIFIED_BY="[Empty name]" ORDER="10" SD_1="1.33" SD_2="1.76" SE="0.18684718003456377" STUDY_ID="STD-Trenkwalder-2013" TOTAL_1="132" TOTAL_2="144" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5486331291006736" CI_START="-0.12863312910067365" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.20999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2016-05-26 04:40:41 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.2241936298674585" Q="0.0" RANDOM="NO" SCALE="10.55" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="144" UNITS="" WEIGHT="100.0" Z="1.215452362403229">
<NAME>Daytime somnolence - MOS</NAME>
<GROUP_LABEL_1>opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [placebo]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [opioid]</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5486331291006736" CI_START="-0.12863312910067365" EFFECT_SIZE="0.20999999999999996" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="3.49" MODIFIED="2016-04-13 12:03:31 +0100" MODIFIED_BY="[Empty name]" ORDER="11" SD_1="1.35" SD_2="1.52" SE="0.1727751794276673" STUDY_ID="STD-Trenkwalder-2013" TOTAL_1="132" TOTAL_2="144" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.4544358786675043" CI_START="-0.1944358786675045" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.1299999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2016-05-26 04:40:45 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.4322491160111368" Q="0.0" RANDOM="NO" SCALE="6.9727293471033995" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="144" UNITS="" WEIGHT="100.0" Z="0.7853487691826213">
<NAME>Trouble staying awake during the day - MOS</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [placebo]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [opioid]</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4544358786675043" CI_START="-0.1944358786675045" EFFECT_SIZE="0.1299999999999999" ESTIMABLE="YES" MEAN_1="4.46" MEAN_2="4.33" MODIFIED="2016-04-13 12:07:12 +0100" MODIFIED_BY="[Empty name]" ORDER="12" SD_1="1.32" SD_2="1.43" SE="0.165531551205335" STUDY_ID="STD-Trenkwalder-2013" TOTAL_1="132" TOTAL_2="144" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.34387554276253807" CI_START="-0.3238755427625385" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.009999999999999787" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2016-05-26 04:40:48 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.9531883266083964" Q="0.0" RANDOM="NO" SCALE="9.811740042635895" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="144" UNITS="" WEIGHT="100.0" Z="0.05870343087495912">
<NAME>Naps during the day - MOS</NAME>
<GROUP_LABEL_1>opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [placebo]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [opioid]</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.34387554276253807" CI_START="-0.3238755427625385" EFFECT_SIZE="0.009999999999999787" ESTIMABLE="YES" MEAN_1="4.34" MEAN_2="4.33" MODIFIED="2016-04-13 12:08:41 +0100" MODIFIED_BY="[Empty name]" ORDER="13" SD_1="1.36" SD_2="1.47" SE="0.17034779485546978" STUDY_ID="STD-Trenkwalder-2013" TOTAL_1="132" TOTAL_2="144" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.4275600356408744E-31" CI_END="-0.358322915652904" CI_START="-1.1016770843470962" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7300000000000001" ESTIMABLE="YES" I2="100.00000000000001" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2016-05-26 04:40:48 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="1.0" P_Z="1.1835557940414166E-4" Q="0.0" RANDOM="NO" SCALE="8.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="144" UNITS="" WEIGHT="100.0" Z="3.8495074594862317">
<NAME>Quality of life - RLS QoL</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [opioid]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.35832291565290386" CI_START="-1.101677084347096" EFFECT_SIZE="-0.73" ESTIMABLE="YES" MEAN_1="2.91" MEAN_2="3.64" MODIFIED="2014-04-01 12:55:57 +0100" MODIFIED_BY="[Empty name]" ORDER="54" SD_1="1.48" SD_2="1.67" SE="0.18963465006440808" STUDY_ID="STD-Trenkwalder-2013" TOTAL_1="132" TOTAL_2="144" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3858808297445597" CI_START="1.074638500765551" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.220377358490566" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="106" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.14172588741182263" LOG_CI_START="0.03126239585532633" LOG_EFFECT_SIZE="0.08649414163357445" METHOD="MH" MODIFIED="2016-05-26 04:40:27 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.002145271374795359" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="154" WEIGHT="100.0" Z="3.069347167770974">
<NAME>Adverse Events</NAME>
<GROUP_LABEL_1>Opioid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [placebo]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [opioid]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3858808297445595" CI_START="1.074638500765551" EFFECT_SIZE="1.220377358490566" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="106" LOG_CI_END="0.14172588741182257" LOG_CI_START="0.03126239585532633" LOG_EFFECT_SIZE="0.08649414163357445" MODIFIED="2014-04-01 12:57:20 +0100" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.06488680174338782" STUDY_ID="STD-Trenkwalder-2013" TOTAL_1="150" TOTAL_2="154" VAR="0.0042102970404857155" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-06-08 02:47:26 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-04-20 00:28:28 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Diagram about search, excluded and included researches.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeEAAAIkCAYAAAAph5OUAAAx7ElEQVR42u3dD6QV+f8/8CVJkkTy
kWRFkiTXJUlWEsnKx0diZSUfX5EkVxLrSnIlkuRKlmStXCuyPpIkkrWSFUmSlSVJkixXVpLMz2v8
5pgz95z5c8+t++/xYHQ78/c9f97PMzPvM/NVkvPVV1/pdLqaHeoNna7XeuOr/IEENAsf68A6gF6O
ma8cSCCElB0m59j5yoEEwkiZYXKOISEMAkmZQQiDQFJmEMKAQFJmEMIgkJQZhDAgkIQwCGGaevz4
sZUgkJTZca/+mU4h/M8//yQHDhxIFixYkMybNy/ZvXt38vfff7f6v3v3Ltm7d2/ab8mSJcnAwEBb
/3Ds2LFk4cKFyfz589PxX79+3aj/TK6MqsabyEoutlG3ad+4cSOZO3du0tfXNyHzFUizu8xRB+zc
uTM9pqPu+O6775I3b97Urlcc9zPvuC9bjtl8DFeG8OHDh5MLFy4knz59SrsIzDhgMvv3709Onz7d
6n/+/Plk165drf5nzpxJhoeHW/2HhoaSLVu21O4/2yvgiZxu2bTiQLx586ZAUuYJKfPJkyeTEydO
tI7rn3/+ORkcHKxdrzjuZ95xP+YJUUK4XggvXrw4PUgyHz9+bPtGE3/n+8ffcVabWblyZfqtt7jh
6/bvtMD3799Pli5dmvT397cd9IsWLUq/WcfZeN6HDx/Ss/X4Vr569erk3r17Y87EY7zoH18AXr58
WTq/KOPBgwfTci5btiwZGRnp+O1yzpw5ybp165K7d+/W2uhV060qZwx7+fLlZMWKFem88wdYp+eW
5v/t1q/OfOsstxCeXWXetm1b8uTJk7Z6Y8eOHbXrFcf9zDruu80rTto6LXfZNq/ablX7aJQpljn2
wTgBLDy1qnSZJiWEi2LHjpXSLYSjf7eDaXR0NF0Be/bsGVf/bIEPHTqUzvPVq1fpZxcvXkx3wvgs
DubYGeLsPHP8+PHk6tWr6d/Xr19P1qxZ0+p39uzZtjPxmFYcuGXzO3fuXHLq1Kn0s7jEtnnz5rYN
md9wt27dSr9o1DkYq6ZbVc4YNi4BZjtlLEP+C03ZN9GyflXzrVpuITz7yhyVXL5eyD6rW6847mfe
cd9pXt9++23pche3QZ3tVjbfKM/Ro0dby7xp06Yx66NsmaZECMdlpdi5M7EC4ptDFOr9+/fpZab4
BlEU94Ti20t0Dx8+bNw/v8D5bz4h7mcUD/j8ARAHX7F/Zu3atWkFkK8M4t522fziW1l+nAcPHrRt
yKhMsoO/SSVWNd2qcnZa1roHXFm/qvlWLbcQnn1l7lRxlVVmxXrFcT/zjvtO86pa7mL/OtutbL4b
N25sa3NUXOaqZZr0EH779m0alvGtKBONKeKzOMBWrVqVfgMsu6wUlxLiUs14+3dazph38XJH/otA
2cHf6QtD2bfITtOLHTU/XKyD+H/sxHFfrO7BWDXdqnJW7YDjPRibrt/icgvh2VfmquOqql5x3M+8
477OPeGyZRvvdst/Vsym4jLXuZw9aSEcB8j333/f1sKxk7gPFPcHyqZTdnBU9a+7Yep+A+/Ur2qj
VI0T4l5GXALbvn17evljPAdjsX9VOT/XwTie9SuQXI6u81ndesVxP/2P+4kI4fFstyZfeKZsCMc3
1fg5wfPnzysneO3atbZ7unGJJn+AFS8fVPWvs0LizDnuJ3cTZ+jdLkvFuMXLG/lvS53mF5c08uPE
F49u6+/Ro0e1d8yq6VaV83MdjFXzbbI+hPDsKHOEUL7BZdyqKv7qoUm94rif/sf9RIRw0+0W+1b+
sw0bNrTlTdz6nPIh/PvvvyfffPNN19/uxn2XCN7w119/pQdfXGfPxOXl/E8Vfvjhh7Sr27/OComb
9VkDgeji//kDPu41xaWicOfOnTENNLJ72tHFzybi4C2b35UrV9KfUmU397du3do2XEw/WkqGqhv7
+fGqpltVzqodKFoTxv2ObCeuezBWzbdquYXw7CtzNLDM7zOXLl1qu0RbVa847mfecV+2HHVDuGq7
5RvHvXjxIm2wVtYwK8oz5UN4+fLlY+4L5IeNwI0b9Nk94WLDhLjcFC3c4ttKNLqK0G3Sv+4Kid8g
xuWumE6s+Kw1XfYtPH6DGMsYN/bzXxKyLwJZo7BoaPbs2bPK+cXvm+OMPZrvRwu9/HBxSSrmkzVx
zw7MOuUpm25VOat2oGjZGONl3xzrHoxV862z3EJ4dpU59o+olLP9LVqc5h/GUVWvOO5n3nFfthx1
Q7hqu2VffmIbRB7FNihOJ744xPLGbdNY5qorIFOqYRYghGd7mZk54otafCGcCseQEAaBpMzMaHHW
Hg3nst8+x1l1WQM6IQwCSZlhgty+fTu9fRqXoOOJWUeOHCn9aZwQBoGkzDALjiEhDAJJmUEIg0BS
ZhDCgEBSZhDCIJAmq0zj+f0uMEEh/PjxY2vJOmGWh3C3h2qMt8yOIagZwsW3TkzFimYilqnJNMre
EuVsYfaul24vS5/p3XhMh3oFpkQI13no9mwL4abzU8HMrhB2Jtx8XTlGEMJdnplZPPDi33iA9ooV
K1rPSM0emJ31j2eoxtuR4kfRmex5n/EQ73hodv7FyXWe1xkPhI9nmMYPrIeHh8dUBGXLVBRPSzl4
8GA6vXh+6MjISNv04kUU8ZzUWNaY1urVq5Nff/216zopGz4bJ8obzzmNYXbs2NH2HNuq8eP5p9nz
UOMtInfv3h2zbuJZqLF+BwYGSjd4L9OqU87ito+HtWfljuHv3bs37u0mhCcvhMdT5m7H/Hjqlap9
s1u902Tf76WOarrvV5WnalmZ5WfC8TD2bActvi0k+scLGSLosod9x5svIjizN1/EQ7Nj56y7gxff
fLFp06YxB0DZMhWdO3eu9XaQmN7mzZvbprd+/fr0DSHZ8sayx8HVbXnrDB+v/Yo3xkT/eOvUvn37
ao+fr5DirTArV65s9Yt1GesnewxbfKGIB6V308u06pSzuO3jTTbZSz3icXH5N9k03W5CePqUuekx
X7UvVO2bnfa9Jvt+r3VU032/qjxly4oQbvuG2GlnLPaPN4sU3wGZf2dw1Q6eBVgmziKr5llWIcY3
1fzyFKfXSf4F13Uq2+Lw+TPfOPD6+vpqjx9BV3w7VSamU3xnatkBO5HT6lTO4naIiqfbO12bbjch
PH3K3PSYr9oXqvbNTuM32fd7raOa7vtV5SlbVoRw5c5YVlHnv+nVnWaxEUfsvL28A7J4tlWcXohL
S/FNds+ePekBWjW/psMXl6Fs/PgmHP+PAzf/TtZsOsXLe53W90RNq9dyNtmXhPD0LXPTY75qX6ja
N+us+7J9v9c6qum+X1WesmVFCE/IztgkRKtCs9cQLg7/008/pd9i40Xk8cDvuLxUNr+mwxe/WFSN
n4VfXNLavn1721s/ygK3m/FOazzlFMKzM4SbHvNV+0LVvll33Xfb93uto5ru+3WO227LihBuvDNG
w4LipZ6yFyk/f/687bMNGzak924zDx8+7CmE4/J2fnmePHnSNnw02BodHe26PMVp1xn+6dOnbeXP
v8Oyavy8R48etfWLdZsft4mm02q6XkK8WLvscrQQnpkh3PSYr9oXqvbNpuu+077fSx3VdN9vctwW
l5VZFsLRsi/udWQ76HhCOBo9RMvHrNHDhQsX0h00/40xa4Tw4sWLtAVuWcOsaLnYSwhH46KhoaHW
9LZu3do2fLTQzFr9RkDHl4B8/+I6qRo+/t62bVvy9u3bdJ7RKCzfMKtq/Dj7jNaSodhgJdZt1sgs
uvh/rJ9ueplWnXIWxaXruLQW7ty5M6ZhlhCemSFcdcw3rVeq9s06675q3++ljmq671eVp2xZmWUh
HC324hth9q1wPCEcsub/0UWrw2fPnrX6ZTtZXKKJHT92vuJ0IjSjOX/8pChaFpZ9S61zUJ45cyZt
eBHTjOnlh//tt9/SRhKxTHEwRAOJfP/iOqkaPv6OecS8YpwI5Hwjjqrx47JU3H/NfrqRHZyZwcHB
9Cw1ph2VQ7fWob1Oq045i96/f5/s3r07HSfmm2+gJoRnbghXHfNN65WqfbPOuq/a93upo5ru+1Xl
qVpWZlEIT0Wxc+cv54IQVmYQwp9JnLFGA4XsN3XxjVVDBQSSMoMQ/gKiJW78tjcu28QTs44cOZKG
MQgkZQYhDAhhQAiDQFJmEMIgkJQZEMIgkJQZhDAIJGUGhDAIJGUGIQwCSZlBCDuYQCApMwhhEEjK
DEIYEEjKDEIYBJIygxAGBJIQBiEMAkmZYSaEsAMKhJGyw+QcO185oEAIWQcwOcfMV8WeOp2uXod6
Q6frtd5QkzjbAGCy6nerQAgDIIQRwgBCGCEMgBBGCAMIYYQwAEJYCAMghBHCAAhhIQyAEEYIAyCE
hTAAQhghDIAQFsIACGGEMIAQRggDIIQRwgBCGCEMgBBGCAMIYYQwAEJYCAMghBHCAAhhIQyAEEYI
AyCEhTAAQhghDIAQFsIACGGEMIAQRggDIIQRwgBCGCEMgBBGCAMIYYQwAEJ4FoVvsQNACCOEARDC
syeIARDCCGEAhLAQBkAII4QBEMIzM4gBEMIIYQCEcG+hpvt8HQBC2FmldQwghIWDIAZgFoewULDO
AYSwQBDCAAhhrHMAISwQrHMAISwQsM4BhLBAsM4BhLBAwDoHEMKfORCuXr06ZrjR0VFPhRLCAEL4
cwbCixcvki1btowZ7vr168nu3bvtKUIYQAh/rkDYvn178ueff44ZbmhoKDl//rw9RQgDCOHPEQgR
tMPDwx2H27VrV7Jt27Zk0aJFycKFC5Njx47Za4QwgBCeiED4448/0pDtNty//vWv5Oeff07//vTp
U/Ljjz8mx48ft+cIYQAh3EsgvHv3Lunv709ev35dOzgiiCOYEcIAQriHQNi3b19y7dq1xsExZ84c
e44QBhDCvQRCnRfTL1myJD1jznz48CFZvXq1PUcIAwjhiQ6E4nBHjhxJTp48mV6Gju706dPJhQsX
7DlCGEAIf+4Qfv/+fbJ///5k3rx5yeLFi5NTp07Za4QwgBAWCNY5gBAWCFjnAEJYIFjnAEJYINi5
rHMAISwQrHMAISwQhDAAQhjrHEAICwTrHEAIC4Tp4vHjx9Y5gBCemSE8keGRn9ZETTee3jUdAlII
AwjhKRPCU2maQhhACE96CMdLGQ4ePJgsXLgwWbZsWTIyMlJ59lrs/9NPP6VvW1qwYEFy6NCh9HnT
VWfC8TamvXv3JvPnz0/fynTv3r1Wv7/++ivZuXNn2m/u3Llp/19//bU1jU5ve4qXTCxatChdhoGB
gUZlFMIAQnhSAuHcuXPpSxkiqN68eZNs3ry5cQj39fUlL1++TKcRYXj48OHKED5+/Hhy9erV9O/r
168na9asafVbv359cuXKldabm4aHh5OlS5d2XaaLFy8mly9fTof9+PFjGrLxtqe6ZRTCAEJ4UgKh
v78/PSvNPHjwoHEI589i//nnn2T58uWVIRyhG6FY15w5c7ouU3wJKE5r5cqVtcsohAGE8KQEQlzu
zYswaxrCxQDMT7PbtIrzLbp//356trxnz55k7dq1pcsU0ypeps6HdlUZhTCAEJ4SIVwWnHX79xrC
cY85zpQvXbqU3L59O3n16lXpPPOBO54yCmEAITwpgbBx48a2S7VPnjwpDbznz5+P6f/o0aPW///+
+++0AVRVCK9atarr5egYf3R0tHSeeevWrWsbvmkZhTCAEJ6UQIgGUENDQ61GS1u3bh1zxnrz5s30
7xcvXqStlouBuGXLlnTcmMYPP/yQ7Nq1qzKE41LzrVu30r/v3LnT1jBrxYoVrdbQEZgbNmxoGzda
TUdDsCxYz54922p4FV38P5apbhmFMIAQnrRAOHPmTPoTo/iJT7Q0zg8bARxBHJd84+z1xo0bY4I1
AvNf//pX2oL5yJEj6dlwVQjHz5h2796dTjvu+UZjqcxvv/2WNqyKfhHO0Yo6P260fI4HduQf2jE4
OJieQcdn8UUhLmHXLaMQBhDC0zIQBI11AyCEhbAQBhDCsysQJuI5ztY5gBAWCFjnAEJYIFjnAEJY
IGCdAwhhgWCdAwhhgYB1DiCEBYJ1DiCEBYIAE8IAQlgIKwOAEJ4WgRCfx7t747nP/f39rc9PnjyZ
Pmd5wYIFycDAQNs48eKEvXv3pi9SWL16dXLv3r22/seOHUvHi/7xIoV42ULZ/OLFCgcPHkyf/bxs
2bJkZGSkbXnjedXZ86vjjUl3794VwgBCeGaE8KFDh9IgzF56EC84uHz5cvrZx48f01CMlyZk4g1I
8VKFcP369bY3IMUbjIaHh1tvNIppRWCXze/cuXOttyDFW442b97c9U1O8ealeLmDEAYQwjMihPNn
qqGvr2/Mu37zwReh2+1dwPFGpPy7e+PveHtR2fzijDg/TrxRKb+8cdachf5MWOcACOGun8eZZ3ye
7+JScL5/N/nhOg3fbX55EfD54eLsN/4fXw5OnDghhAGE8MwN4U5BWhaaVf26vVO47jgh7iPHpe/t
27cnR48eFcIAQnhmhnA0fhodHe06rVWrVnW9HB3jFi9H59+01Gl+GzdubBvnyZMnXZf30aNH0ybc
hDCAEG4cwtG4KmsoFV38P1o5Z6JhVlwiDnfu3BnTMOv8+fOtcS9cuJCGdtn8rly5kgwNDbUaZm3d
urVtuJh+tJAO0UCr7ExcCAMI4WkdwmFwcDD9yVCcxe7cubPVkjm8f/8+2b17dxqG0RArGlLlZT9R
ii5aRj979qxyfmfOnEkbcMXPoqJFdX64uBQd84nL5DHPLJCFMIAQFghY5wBCWCBY5wBCWCBgnQMI
YYFgnQMIYYEghAEQwljnAEJYIFjnAEJYIGCdAwhhgWCdAwhhgaCc1jmAEBYIQhhACM+0cIrP49nM
S5cuTfr7+1ufnzx5Mn2Oczz/eWBgYMw4ly5dSp/1vHjx4uSXX35JX9wQz5qOZzvHSxbysmdJz58/
P30RxMuXL5N3794ly5cvT59DnRdvU4o3MdVZjnjhw8GDB9P5Llu2LBkZGRHCAEJ4eoXwoUOH0kDL
XtIQL1C4fPly+tnHjx/TcDt9+nTbOPv27Uv7/e9//0tDcP/+/en/i285inAeHh5uvVUpph0vdQgH
DhxI++edO3cuDd46yxHDZm97ircvbd68WQgDCOHpFcJxZprX19c35n3BK1eu7DpO/D///uH8vOLt
R8X3C8cZdHj69Gl6NpzNK/79+uuvW9OuWo44c89PO97mJIQBhPC0CuGiOJONz/NdvEaw2zhl/8+P
l59+5ptvvknPdkO8Vzhem1h3OYrvFY7AFsIAQnhah3Cn4KwbusX/F4Oy2P/69evJ6tWr07/jXvDt
27drL0fVtIUwgBCediEcYZi/vNxLCMe0ipej582b1zb8ihUr0vu7cSm6yXJs3LixbdpPnjwRwgBC
eHqHcDSWyho8RRf/j1bN4wnhGPf8+fOtaV24cCFZtWpV2/DR2CpaN+cbXdVZjrh8PTQ01GqYtXXr
ViEMIISndwiHwcHBtNVznLXGfdqs5XTTEA7ZT5Sii5bRz549a+v/9u3bdD4RpE2WI5w5cyZt6BU/
Y4rW1EIYQAhPmxDGOgcQwgLBOgcQwgIB6xxACAsE6xxACAsErHMAISwQrHMAISwQsM4BhLBAsM4B
hLBAwDoHEMICwToHEMICQQgDIISxzgGEsECwzgEQwljnAEJYIFjnAEJYIGCdAwhhoWBdAwhh4YB1
DCCEJyYkdJ+vA0AIO7MEQAgjhAEQwkIYACGMEAYQwghhAIQwQhhACCOEARDCCGEAIYwQBkAIC2EA
hDBCGAAhLIQBEMIIYQCEsBAGQAgjhAEQwkIYACGMEAYQwghhAIQwQhhACCOEARDCCGEAIYwQBkAI
C2EAhDBCGAAhLIQBEMIIYQCEsBAGQAgjhAEQwkIYACGMEAYQwghhAIQwQhhACDNFwrfYASCEEcIA
COHZE8QACGGEMABCWAgDIIQRwgAI4ZkZxAAIYYQwAEK4foDppkYHwCwKYRW/7QEghFX42C4AsyOE
VfS2D4AQVslj+wAIYWwfACGskrfT2T4AQhjbB0AIq+SFMIAQVslj+3yJ8ut0Og/5mXUh/M8//yQH
DhxIFixYkMybNy/ZvXt38vfff7f6v379OvnPf/6T9ps/f37a/82bN63+7969S/bu3Zv2X7JkSTIw
MNA2fvy9c+fOdNyYx3fffdc2vpAUwr4ggmNm1obw4cOHkwsXLiSfPn1Ku2PHjqVBm9m6dWvyyy+/
tPrH39u2bWv1379/f3L69OlW//Pnzye7du1q9T958mRy4sSJVv+ff/45GRwctNMLIgEMjh0hvHjx
4jQcMx8/fkzPajNz584dM07+sxg2P378vXDhwtb/I7CfPHnSNv0dO3aULuf9+/eTpUuXJv39/W1h
vmjRovRsOs628z58+JCejcfZ9urVq5N79+619Y8vFjFe9N+yZUvy8uXL0vlFGQ4ePJiWY9myZcnI
yEjb+rtx40a6DubMmZOsW7cuuXv3rgNKmcExJIR731gRaBFIxTPhzNWrV5NvvvmmawjH+PkQjyDL
988+K1vOQ4cOpeO8evUq/ezixYvJ5cuX088ixCMU4+w7c/z48XS5wvXr15M1a9a0+p09ezYZHh5u
nYnHtCKwy+Z37ty55NSpU+lncel88+bNbesvAvjmzZvp37du3UpWrlzpYFJmcAwJ4d43VlwujlDL
PH36ND1bzhoExN/xWSYCLS5BR2C9f/8+vbwdZ4h1z6Q7LWf+TDX09fWNCfJ88EXoFvtn1q5dm34x
yH9JiHvXZfOLM+L8OA8ePGhbf/ElJQt9B5Myg2NICE/Ixnr79m3acCrONjPRqCrOJrMzyTNnzrTd
842GVzFOBOuqVavSM8P8mXA+kOuGcKfhi60Dq4K+7vy7zS8vyp0fLsoY/48vB3G/28GkzOAYEsI9
bawI3u+//35My+VO93zj3mo3cf837qNmOl16rrocXSdI64Z6p375edQJ4U7DxX3kuPS9ffv25OjR
ow4mZQbHkBAe38aKM+D4mdLz58/H9CsGboRwNHLq5tq1a8mePXta/4+Qip9BZeKSdTSOarKc0fhp
dHS06zhxBt7tcnSMW7wcnT9T7zS/jRs3to0TXyy6rb9Hjx5NyIEghAHH0CwM4d9//z1taBW/B+4k
Gi1dunQpPVOOoItGS9FyOBP3YyN4w19//ZWGbtxDzUSr5qyRU3QxrbJLuJ2WMy6H56cR/88HedzD
jkvE4c6dO2MaZmX3rKOLn2NFaJfN78qVK8nQ0FCrYVY0TssPF9OPFtIhGmiVnYkLJGUGx5AQ7rqx
li9fXvpEljhzjSCOs8foIoDjs0wEbjRkyu4JFxssRYvjCLFs/G+//bbtYR51lzN+WxyXsWMacZ86
a8mcLWP8tjmWIRpi5b8EhOwnStFFQ7Jnz55Vzi/ufUcDrvhZVLSozg8Xl6JjPnGZPOaZBbKDaWLK
3OsDZKr6h2hh//XXX6fDbNiwIb2ioQKevGWZ7PGFsBC2sXyjVeb/r9cHyFT1/+OPP9JbDnH7JfrH
lY/81RP7jBC2DwhhG8vBNGvL3OsDZKr6R5uFuNLRZDln2gNkui17/NIhbunkp5s9XKesTFWNHfOf
VZWlat3WGV+9IYRtLGyfCSpz0wfIVPVfsWJF8vjx40bLOZMeIFO27DG/uDyf/e4/ppM9F6CsTE1C
uKosVeu2anzHkBC2sbB9JrDMTR8gU9U/AiuCKs7msnvGVe0UZtIDZKqWPUIwgi6CL24N1ClTkxCu
KkvV8lWN7xgSwjYWts8ElXk8D5Cp6h/zjYZf8bO37Ew0/7O6Oss5nR8gU7XsWRDGF4NY/3XK1CSE
q8rSdN0Wx3cMCWEbC9tnAso83gfIVPWPe4n5M6non7/nXGc5p/MDZKqWPcSvGOLM90uEcLH/eNat
EBbCNha2zwSWuZcHyFT1L77Fq+opcDPtATJVyx4t0+OebPymP385uqxMZSEc2zD/WVVZqpavybpQ
bwhhG4tZu32KvzmvW+ZeHyBT1T/unUaXfwd2NEZqspzT+QEyZcseDbM2bdrUFoh//vlnZZm6NRJ7
8eJFensg37+qLFXrtmp89YYQtrGwfXIh3O1BMJ/rATJV/UOEYDRmyh7+kgVNk20znR8g023ZY5nz
P1GKv6N/VZnyy5J9CYhliS8XsSzFMpWVpWrd1hlfvSGEbSzlHtdydguumdoB6nUhbCe1nFPoTBgQ
wrNmY5U9aafqCTlNnyJU1T+mGQ1C4mEK2WW17N5SnfGn85N03BMG1BuzMITLnrRT9YScpk8Rquof
04z7P9mDCooNTGbyk3S0jgYcQ7MwhMuetFP1hJymTxGq6t9pmrPlSTpCGHAMzcIQLnvSTt0f5+eH
r3rSTVn/Oj/yn6lP0hHCgGNoFoZw6PaknaYhXPWkm6r+VSE8k5+kI4QBx9AsDeFM8Uk7dZ+Qk6l6
0k1V/6oQnslP0hHCgGNoFoZw2ZN26j4hJ1P1pJuq/lUhPJOfpCOEAcfQLAzhsift1H1CTl7Vk27K
+leFcJ3pT9cn6QhhwDE0C0MY20eZwTEkhG0sB5MyA44hIYzto8zgGBLCNpaDSZkBIWxjYfsoMziG
hLCN5WBSZkAI21jYPsoNjh0hrLKzfZQdHDNC2EbD9hlv+XU6Xb1uxtcHKnlsHwAhrJIXwgBCWCWP
7QMghFXytg+AEFbJY/sACGGVvO0DIIRV8tg+AEJYRW+7AAhhFT62B4AQblX8Ok++ARDCOIMEQAgL
YQCEMEIYQAgjhAEQwghhACGMEAZACAthAIQwQhgAISyEARDCCGEAhLAQBkAII4QBEMJCGAAhjBAG
QAgLYQCEMEIYQAgjhAEQwghhACGMEAZACAthAIQwQhgAISyEARDCCGEAhLAQBkAII4QBEMJCGAAh
jBAGQAgLYQCEMEIYQAgjhAEQwghhACGMEAZACM/K8C12AAhhhDAAQnj2BDEAQhghDIAQFsIACGGE
MABCeGYGMQBCGCEMwOcI4U4/idHpdF/5uRjweUNYpQKuUACTEMIqExDEwKTUISoREMSAEAYhDAhh
QAgDQhiEMCCEASEMCGEQwoAQ/jIeP348pabzuaeJEAaEcMvVq1crK5obN24kc+fOTfr6+hpXXFXT
njdv3oQUdqKmUzbNuhWyivvzhF7T/VAIA1M6hF+8eJFs2bKlsqKJiu/mzZvjqriqpj1RldznqCzH
O00V9+dZ5033QyEMTOkQ3r59e/Lnn3+WVjSdnqnbafhuwdt02uHkyZPJokWLkgULFiQDAwOtz7/7
7rvkzp07bWdGO3bsqPXc37/++ivZuXNnMn/+/LQyX716dfLrr7+2Lcv9+/eTpUuXJv39/ZXl/vDh
Q7J37950ejGte/fudS1zt/Lkz+7mzJmTrFu3Lrl7927X9VVVhrJpVc1nvMvYy3Q/ffqUHDx4MFm4
cGGybNmyZGRkpOv267aNjx07lk471kl8oXz58mXXbSqEgSkTwkNDQ8nw8PC4zlYnKoQ79b948WJy
+fLltIL++PFjWjGfPn067ffq1atkw4YNab/3798nK1euTJ4+fVprPuvXr0+uXLmSjhtdlD0q5/xy
HDp0KO0X86kq9/Hjx9NL+eH69evJmjVrOg5XVp7i2d2tW7fSMo23DGXTKuvXyzL2Mt1z584lp06d
Svu/efMm2bx5c+WXtryzZ8+m6yBbHzG/+GJUtk2FMDDpIfzHH38k27ZtG3dQfs4Qjvt9UWnmFSv2
qLyjMj98+HBPlWWcveXHz59FVZU7Qre4nJ2GqypPhGgW5uORL0PZtMr69bKMvUw3zk7jikLmwYMH
jUJ47dq1bePH30uWLCndpkIYmNQQfvfuXVr5vX79ekqGcJxZFS895oMmq9yjsn379m2jyjIuTcYZ
7J49e9IKvGo5y8ody1mnTFXlibPH+CzKdOLEiZ7KUDatsn69LGMv0y2uwwjsJiFc3C+K05yIABXC
wISG8L59+5Jr1641qmgmIoS73dOrU7EWffvtt+mZaJMQ/umnn9JxLl26lNy+fTu9PPklQrhOeSJY
45J23KM/evTouMtQNa1u/XpdxvFOt9M6bBLCVeMLYWDKhfB4XmReFcLPnz+fsDPhaNwzOjradfgL
Fy6k9xkjiJpcjo7GP/npli1znXKvWrWq1uXoqvLkPXr0qLQcVWWoO61iv4laxqbT3bhxY9vl5CdP
njTaD2P6xcvR+Z+VCWFgyoXweCqaTmcgWWOc+JlTtNgdbwhHq9a4b5dVptHYJmusE138P1q9hjjz
27RpU1slHK27O02naMWKFa2WxFHZRwOvquUsTrPYMCsuxYZosd2tYVZZeUKMFy2MQ6zTsjPsqjKU
TausXy/L2Mt0o5FZNBDMGmZt3bq1ccOs8+fPt6YfX9Diy5EQBmZ0CGeVbVxujEovKuHxhnA0sIqz
l/wZzODgYHrWF59FwGctW3fv3t32E6X4O/p3m07eb7/9ljYKiuWO4Cg+pKTTchanmR8mWmfH8sT0
4t5sNCrqNq1u5QlxKTfGj3UZ08oCbTxlKJtW1XzGu4y9TDecOXMmvb8fP2OKRndNQjhkP1GKLlpG
P3v2TAgD0yuEASEMCGEQwoAQBoQwIIRBCANCGIQwgBAGIQwIYRDCAEIYhDAghL+Ux48f28oIYWBm
hXCT8cY7bJOndHX7u9vTsUAIA7MihL9E5dZtWBUkQhiYliF88uTJ9Hm98czdgYGB0oqn6bDxrODF
ixcnw8PDpWe08XKEeN5vvChhx44dXZ+/XOfViOvXrx9Txo8fPybLly9P36EMQhiYEiEcD8qP1wHG
m2ciqEZGRtKXFXSqeJoMG8PF+2Szt+LEG4/KwjReZff69et0+HjHcbzruG4IF/+ON/DcvXu3rZyx
PPv377cnIISBqRPCfX19Y96FG2/n6VTxNBk2C9VMnNmWBWj+zDfmEfMabwhnL5XP6+/vTx4+fGhP
QAgDUyeE45Vzxcu58Sq6ThVPk2GLDaUiWJu84jD/LtqmIRzifbtPnz5tfQGIEAYhDEypEM6HaFXF
02TY4gvpm4ZwPsTHE8LxgvgDBw6kf8e95h9//NFegBAGplYIr1u3LhkdHa1V8TQZdsOGDem94Exc
Ci4L0OysNXz48CFtRNVLCMe8o5FXXBKPhmTv37+3FyCEgakVwmfPnk1OnTqVnqlGF//fsmVLx4qn
ybDFhlkxXFmAbtu2LXn79m06fMyjacOsCNxoYR0Bnokz4H//+9/JoUOH7AEIYWDqhXAYHBxMf0oU
l4B37tyZvHr1qmvF02TYuCQcZ6HLli1LW1aXXWKO/jFsDBOBHIHaJISjlXaMm5/HvXv30mE8TQsh
DEzZEP4S4nJw/hLzlxBfEKKBFghhYFaF8JIlS9KfCmW/KT527Fh6efpLifnGWfuJEydsfYQwMLtC
+Pbt2+nPguLycDwx68iRI2kYfylxjzgua2uQhRAGZl0IgxAGEMIghAEhDEIYEMKAEAaEMAhhQAgD
QhgQwiCEASEMCGFACIMQBoQwCGEAIQxCGBDCIIQBhDAIYWDK1R8qERDAwCSGsMoEBDAwiSGcVSo6
na5eBzChIYwzLgCEMEIYQAgjhAEQwkIYACGMEAZACAthAIQwQhgAISyEARDCCGEAhLAQBkAII4QB
EMJCGAAhjBAGEMIIYQCEMEIYQAgjhAEQwkIYACGMEAZACAthAIQwQhgAISyEARDCCGEAhLAQBkAI
I4QBEMJCGAAhjBAGEMIIYQCEMEIYQAgjhAEQwkIYACGMEAZACAthAIQwnyN8ix0AQhghDIAQnj1B
DIAQRggDIISFMABCGCEMgBCemUEMgBBGCAPwOUK4009idDrdV34uBnzeEFapgCsUwCSEsMoEBDEw
KXWISgQEMSCEQQgDQhgQwoAQBiEMCGFACANCGIQwIITrefz4sTWNEAZoEsLHjh1LFi5cmMyfPz/Z
vXt38vr163HNZN68eRNa0an0vnxQTPb4QhiYVSF85syZZHh4OPn06VPaDQ0NJVu2bJm0SkpFJ4SF
MDBrQnjlypXJP//80/bZ3Llzu07oxo0baf85c+Yk69atS+7evduqoIrP2+00z/xnEfoHDx5Mz8KX
LVuWjIyMlJ4Jnzx5Mlm0aFGyYMGCZGBgoNZyFX399dfJ27dv07+fP3+ezuOPP/5I/x9XAKJ/nfnF
ePfv30+WLl2a9Pf31xqnk27Df/fdd8mdO3fayrdjx4707w8fPiR79+5Nr1ysXr06uXfvXu0rCU3W
f1V56owvhAFq3hMeHR1NK909e/Z0HSaC7ubNm+nft27dSkO8WyVVFQLnzp1LTp06lVbmb968STZv
3tw1RC5evJhcvnw5Hfbjx49phX/69Olay5X3/fffJ9euXUv//uWXX9JL6DHt7P8RbnXmF8t26NCh
tP+rV69qjVNUNnxMc8OGDWm/9+/fp+V5+vRp2u/48ePJ1atX07+vX7+erFmzZlwhXLX+q8pTNb4Q
BqgZwnHmFWc70T18+LDrcHHmlwVAVSVVFQJxBhlndZkHDx50DZG+vr60si+exddZrryffvopOXDg
QPr3//3f/6VfOLIvHfv27UuDps78YtlevnzZ1r9qnKKq4SMEI+gi+A4fPtz6PEK3ON54Qrhq/Vct
X9X4QhigwZlwiEZacTm3mzjLjGlFBX3ixImeQrh42Tsq/G4hEsMWL3nHpec6y5UXZ5Pr169P/45y
Pnr0KFm+fHn6/7i0G5eo68yvU9mqxhnP8FGeJUuWtC6hd1pv4w3hqvVftXxV4wthgIYhHJcdyyr5
EPdC4zLo9u3bk6NHj05YCJeFSFmYVS1X0eLFi9PLp1n4rlixInny5Enr/3Xm16lsdZax6fDffvtt
eub7JUK46TqvGl8IA1SEcFzGjUDKxOXFOPOqI84iyyr94v+zhlCZjRs3tl3OjCDsNr04a4171uNZ
rqJdu3Yl//3vf1uXobNL0vl74VXz6zT9JstYZ/gLFy6k92QvXbrUdjl61apV47oc3XT9Vy1f1fhC
GKAihOPyc1y+zX6i9MMPP6RdN3FWFi11QzSEyp8NRWvduE+aVcz5xlIvXrxIdu7c2VaRXblyJf1J
VNawZ+vWrV1D5OzZs61GQNHF//M/pSpbrqLz58+nXzQi5MKPP/6YLnsEXt35dVqfVeM0GT4aZm3a
tKktEP/888/072iYFZffQ7Sg7tYwq9f1X1WeqvGFMEBFCMfl52jlG62Eo1FWhHKZuOS7du3a9FJl
VPJZ8IVoQBTTyR7akYVhDBtnbzFscTnid8oRiPEzmGiIVHYmNzg4mP4cJqYfgZK1Sq5arqLff/+9
7adJWYOiLOTqzK/b+iwbp8nw8dCU/E+U4u/oH6K1dPSPckaZY/k7LVev679OearGF8IAnh0NQhgQ
wiCEASEMCGFACIMQBoQwIIQBIQxCGBDCgBAGhDAIYUAIgxAGEMIghAEhDEIYQAiDEAaEMAhhACEM
QhgQwiCEASEMCGHgi9QfKhEQwMAkhrDKBAQwMIkhnFUqOp2uXgcwoSGMMy4AhDBCGEAII4QBEMJC
GAAhjBAGQAgLYQCEMEIYACEshAEQwghhAISwEAZACCOEARDCQhgAIYwQBhDCCGEAhDBCGEAII4QB
EMJCGAAhjBAGQAgLYQCEMEIYACEshAEQwghhAISwEAZACCOEARDCQhgAIYwQBhDCCGEAhDBCGEAI
I4QBEMJCGAAhjBAGQAgLYQCEMJ8jfIsdAEIYIQyAEJ49QQyAEEYIAyCEhTAAQhghDIAQnplBDIAQ
RggD8DlCuNNPYnQ63Vd+LgZ83hBWqYArFMAkhLDKBAQxMCl1iEoEBDEghEEIA0IYEMKAEAYhDAhh
QAgDQhiEMCCE63n8+LE1jRAGaBrC79+/T1atWtXTTObNmzdpFd1EVZC9Tmeyx0cIA9MshD9+/Jjs
2rVrSgTIZFd0QhjbBviiIbxly5bkxYsXtSqZGzduJHPnzk3mzJmTrFu3Lrl7926rgio+b7fT9PKf
ffr0KTl48GCycOHCZNmyZcnIyEja/9mzZ8n69es7fllYvnx58u7du9Lpxt+XL19OVqxYkS5nLO/N
mzdb/T98+JDs3bs3mT9/frJ69erk3r17XacznuXPO3nyZLJo0aJkwYIFycDAQFu/OuMjhIEZHsK3
b9+uXcnkA+3WrVvJypUru1ZSVSF27ty55NSpU2kYvXnzJtm8eXOr/9atW1sBn4lg3b9/f2UFGX/v
3LkzefnyZfr/WN5Y7szx48eTq1evpn9fv349WbNmzbhCuGz5w8WLF9Nljv7xBSJC9vTp07XHRwgD
syCEm1QyS5cubQVY1fhVIdbf35+elWYePHjQ6h/huH379rZxY/iHDx/WCuEsgDv1j9CN4KsznfEu
f+jr6xszn/yXlqrxEcKAEG4TZ78xXATMiRMnegrh/NlpiMDK94/LyU+fPm0FVIRWnWVvOt+Jmk5x
+aN/8TJ9XB6vOz5CGBDCY9y/f791pnr06NEJC+Fi/6GhoeTAgQPp33EP98cff5zSIVzsnw/cTqrG
RwgDQrirR48elYZW8f/Pnz9v+2zjxo1tl2OfPHnS1j/uk0bjqdevX6eNm+JnVBMRnvFTrPFcjm66
/NFwbXR0tOsyV42PEAaEcJu4nxotpEOxwVMEZtyLzYIl34grWl9HY6n8PK5cuZKe7WYNk6IxVnEZ
4gz43//+d3Lo0KHay14VwtEwKy6rhzt37nRtmNXr8p89e7bV8Cq6+H+0RG9SfoQwIIRb4lL02rVr
Wz/9yQI5RMvfeGBH9tCOLKRj2Dj7jGGL8zhz5kyyZMmS9Ew3WhMX+8fPh+KzqqdxNQnhOKPevXt3
umxRlrjf3Gm4iVj+wcHB9CdIsU4ixF+9etVofIQwMEtCeCqK0IoGWiCEASH8BcVl2jiTLLbCBiEM
COHPLO4xb9u2rbRBFghhQAiDEAYQwiCEASEMQhhACIMQBoQwCGFACANCGBDCIIQBIQwIYUAIgxAG
hDAghAEhDEIYEMIghAGEMAhhYKrXHyoREMDAJIawygQEMDCJIZxVKjqdrl4H0Kv/B9eHwIbHFhKQ
AAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-06-08 02:47:26 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias criterion for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAU4AAAFzCAIAAADe1XdNAAAQfElEQVR42u3dv25cxRfA8ZWQEIUL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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-06-08 02:47:26 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 opioids and placebo, outcome: 1.1 RLS symptoms - IRLSSS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuUAAACACAMAAACbQucMAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-06-08 02:47:26 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 opioids and placebo, outcome: 1.3 Drug responders - IRLSSS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqkAAACQCAMAAAAcEgK5AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-06-08 02:47:26 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.05" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 opioids and placebo, outcome: 1.5 Remitters - IRLSSS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqwAAACQCAMAAAD6O8n9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2016-06-08 02:47:26 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.12" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 opioids and placebo, outcome: 1.12 Adverse Events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqwAAACQCAMAAAD6O8n9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2016-08-17 14:30:22 +0100" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2016-08-17 14:30:22 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-08-17 14:09:35 +0100" MODIFIED_BY="[Empty name]">GRADE assessment</TITLE>
<DATE_SUBMITTED>
<DATE DAY="30" MONTH="6" YEAR="2016"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2016-08-17 14:11:45 +0100" MODIFIED_BY="[Empty name]">
<P>Date of Submission: 30-Jun-2016</P>
<P>Name: Andrew Moore</P>
<P>Email Address: <A HREF="mailto:andrew.moore@ndcn.ox.ac.uk">andrew.moore@ndcn.ox.ac.uk</A>
</P>
<P>Affiliation: University of Oxford</P>
<P>Role: Author and editor</P>
<P>
<B>Comment: </B>
</P>
<P>First of all, it is really nice to see a review on restless legs. Typically for RLS there are few studies, and this review included only a single study.</P>
<P>I have no real issue with the way the review was done, but I am concerned that the GRADE assessment of moderate quality evidence may overstate how much reliance we can put on the evidence. My concerns are twofold, and both of them are based on solid evidence which does not yet form part of Cochrane guidance.</P>
<P>The first is the issue of imputation. In chronic pain it is becoming increasingly clear that any benefits of opioids derives from the use of last observation carried forward in a situation of high dropout rates (30-60%, often early). LOCF means that someone might benefit at 2 weeks, but cannot take the tablets and so drops out. The beneficial result at week 2 is then treated as if it occurred at week 12. But if the patient cannot take the tablet, then they can't get benefit. In terms of the patient, the treatment has failed, but the imputation method treats it as a success. In chronic pain, even in studies examined by the FDA, LOCF overstates treatment effect to a very large degree - so that as yet no opioid has been shown to be effective if an outcome of useful pain relief AND taking the tablets at 12 weeks is used. The results show either no difference between opioid and placebo, or even statistically worse than placebo. There are analyses of the use of imputation methods showing that situations where LOCF is used are problematical when adverse event withdrawals are higher with active than placebo, as in the trial in this review. In the USA there have been major reports recently highlighting concern at use of LOCF.</P>
<P>I have read the paper several times, and I am not cure how data were handled to achieve an IRLSSG response of 50% reduction, or PGIC of much or very much improved. Thought these figures imply NNTs of about 4 and 3 respectively - useful degree of benefit - it might have been much less useful if all withdrawals were considered treatment failure. Unless one knows that, then moderate quality overstates the case.</P>
<P>Probably less important but also relevant is the question of study size. Small size is also known to be associated with overestimation of treatment effects, as well as issues of random chance affecting estimation of magnitude of effect. At the sizes in the single trial, then the latter at least might apply, though the study itself was impeccably conducted. Another reason to be cautious about how good the result is. I can provide references for all this if needed.</P>
<P>GRADE is useful as long as the GRADE of evidence is appropriate, and how much value there is in having three levels that basically say that we don't know that the results are much good. On balance I would suggest that further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate - Low quality.</P>
<P>But thanks again for demonstrating just how little evidence there is in this important condition. It is very much the same as chronic pain.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2016-08-17 14:13:01 +0100" MODIFIED_BY="[Empty name]">
<P>We are very much thankful to Dr. Moore for the time spent analyzing our Cochrane Systematic Review on Opioids for restless legs syndrome (RLS) treatment. We agree with the comments and arguments about the last observation carried forward (LOCF). Including observations from patients that dropped out early in the study could bring a real bias to the results. The LOCF implies in an imputation, which could not be of value to patients suffering from a chronic condition like RLS. The drug bears a potential benefit, but could not be of value in the real-world, which means that at the end of the protocol it would be similar or worse than the placebo. To avoid the early drop out problem influencing negatively the results, we should apply the concept of the worst scenario, i.e., early dropout must be considered as treatment failing. This was not done in the single studied included.</P>
<P>Although the primary study was rigorously conducted, and many centers collaborated, the number of patients included in the trial was small when we aim to demonstrate unequivocal evidence.</P>
<P>Taking into account all the issues raised above, we agreed in downgrading the level of the evidence to low. We have already incorporated this change in the RevMan.</P>
<P>We appreciate the opportunity to address this issue in our review.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2016-08-17 14:30:22 +0100" MODIFIED_BY="[Empty name]">
<P>Author team. </P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2013-10-16 22:07:15 +0100" MODIFIED_BY="Ema Roque">
<APPENDIX ID="APP-01" MODIFIED="2008-11-06 16:04:59 +0000" MODIFIED_BY="Ema Roque" NO="1">
<TITLE MODIFIED="2008-11-06 16:03:40 +0000" MODIFIED_BY="Ema Roque">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-06 16:04:59 +0000" MODIFIED_BY="Ema Roque">
<P>"#1 RESTLESS LEGS SYNDROME<BR/>"#2 (restless next leg*)<BR/>"#3 (ekbom* next syndrome)<BR/>"#4 (periodic next leg next movements*)<BR/>"#5 (periodic next limb next movements*)<BR/>"#6 (PLM or PLMS or PLMD)<BR/>"#7 (#1 or #2 or #3 or #4 or #5 or #6)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-10-16 22:06:15 +0100" MODIFIED_BY="Ema Roque" NO="2">
<TITLE MODIFIED="2008-11-06 16:04:02 +0000" MODIFIED_BY="Ema Roque">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-16 22:06:15 +0100" MODIFIED_BY="Ema Roque">
<P>"MEDLINE search strategy (1966 to most recent):<BR/>"#1 restless legs syndrome [Text Word]<BR/>"#2 restless legs syndrome [All Fields]<BR/>"#3 ekbom syndrome [All Fields]<BR/>"#4 (periodic [All Fields] OR movement [All Fields]) AND (leg OR legs)<BR/>"#5 (periodic [All Fields] OR movement [All Fields]) AND (limb OR limbs)<BR/>"#6 (periodic [All Fields] OR movement [All Fields]) AND extremities [All Fields]<BR/>"#7 nocturnal myoclonus syndrome [All Fields]<BR/>"#8 periodic limb movement disorder<BR/>"#9 periodic limb movement disorders<BR/>"#10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9<BR/>"#11 "morphine" [All Fields]<BR/>"#12 "hydromorphone" [All Fields]<BR/>"#13 "levorphanol" [All Fields]<BR/>"#14 "meperidine" [All Fields]<BR/>"#15 "methadone" [All Fields]<BR/>"#16 "propoxyphene" [All Fields]<BR/>"#17 "codeine" [All Fields]<BR/>"#18 "pentazocine" [All Fields]<BR/>"#19 "hydrocodone" [All Fields]<BR/>"#20 "oxycodone" [All Fields]<BR/>"#21 "fentanyl" [All Fields]<BR/>"#22 "tramadol" [All Fields]<BR/>"#23 #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22<BR/>"#24 #10 AND #23</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-10-16 22:06:48 +0100" MODIFIED_BY="Ema Roque" NO="3">
<TITLE MODIFIED="2008-11-06 16:04:15 +0000" MODIFIED_BY="Ema Roque">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-16 22:06:48 +0100" MODIFIED_BY="Ema Roque">
<P>"EMBASE search strategy (1980 to most recent):<BR/>"#1 Restless Legs Syndrome/<BR/>"#2 restless leg$.tw<BR/>"#3 Ekbom$ syndrome.tw<BR/>"#4 periodic leg movement$.tw<BR/>"#5 periodic limb movement$.tw<BR/>"#6 (PLM or PLMS or PLMD).tw<BR/>"#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6<BR/>"#8 "morphine" .tw<BR/>"#9 "hydromorphone" .tw<BR/>"#10 "levorphanol" .tw<BR/>"#11 "meperidine" .tw<BR/>"#12 "methadone" .tw<BR/>"#13 "propoxyphene" .tw<BR/>"#14 "codeine" .tw<BR/>"#15 "pentazocine" .tw<BR/>"#16 "hydrocodone" .tw<BR/>"#17 "oxycodone" .tw<BR/>"#18 "fentanyl" .tw<BR/>"#19 "tramadol" .tw<BR/>"#20 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19<BR/>"#21 #7 AND #20</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-10-16 22:07:15 +0100" MODIFIED_BY="Ema Roque" NO="4">
<TITLE MODIFIED="2008-11-06 16:04:33 +0000" MODIFIED_BY="Ema Roque">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-16 22:07:15 +0100" MODIFIED_BY="Ema Roque">
<P>"LILACS search strategy (1982 to most recent):<BR/>"#1 síndrome das pernas inquietas [Palavras]".<BR/>"#2 (tw syndrome or tw sindrome) and (leg or legs or pierna$ or perna$ or limb$) [Palavras] and inquieta$ or restless<BR/>"#3 (movement$ and periodic) [Palavras]<BR/>"#4 #1 OR #2 OR #3<BR/>"#5 "morphine" [Palavras]<BR/>"#6 "hydromorphone" [Palavras]<BR/>"#7 "levorphanol" [Palavras]<BR/>"#8 "meperidine" [Palavras]<BR/>"#9 "methadone" [Palavras]<BR/>"#10 "propoxyphene" [Palavras]<BR/>"#11 "codeine" [Palavras]<BR/>"#12 "pentazocine" [Palavras]<BR/>"#13 "hydrocodone" [Palavras]<BR/>"#14 "oxycodone" [Palavras]<BR/>"#15 "fentanyl" [Palavras]<BR/>"#16 "tramadol" [Palavras]<BR/>"#17 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16<BR/>"#18 #4 AND #17</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 study included&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 studies were excluded&lt;/p&gt;&lt;p&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 full-text articles assessed for eleigibility&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;2890 records screened&lt;/p&gt;" WIDTH="95">
<FLOWCHARTBOX TEXT="&lt;p&gt;45 duplicated records removed&lt;/p&gt;" WIDTH="84">
<FLOWCHARTBOX TEXT="&lt;p&gt;2933 records identified through database search&lt;/p&gt;">
<OUT TEXT="&lt;p&gt;02 records identified through other sources&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;2886 records excluded&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>